Technological University Dublin

ARROW@TU Dublin
Masters

Science

2007

The Clinical Utility of Forced Vital Capacity Measured at Six
Seconds in the Spirometric Detection of Airways Obstruction
Janine Kelly
Technological University Dublin

Follow this and additional works at: https://arrow.tudublin.ie/scienmas

Recommended Citation
Kelly, J. (2007). The Clinical Utility of Forced Vital Capacity Measured at Six Seconds in the Spirometric
Detection of Airways Obstruction. Masters dissertation. Technological University Dublin. doi:10.21427/
D7H030

This Theses, Masters is brought to you for free and open
access by the Science at ARROW@TU Dublin. It has been
accepted for inclusion in Masters by an authorized
administrator of ARROW@TU Dublin. For more
information, please contact arrow.admin@tudublin.ie,
aisling.coyne@tudublin.ie.
This work is licensed under a Creative Commons
Attribution-Noncommercial-Share Alike 4.0 License

The clinical utility of forced vital capacity
measured at six seconds in the spirometric
detection of airways obstruction.

Janine Kelly
A thesis presented to
The School of Physics
Dublin Institute of Technology
MPhil
2007

Supervisors:
Dr Patrick Manning
Dr Patrick Goodman
Dr Matthew Hussey

i

Declaration

I certify that this thesis which I now submit for examination
for the award of Master of Philosophy, is entirely my own
work and has not been taken from the work of others save
and to the extent that such work has been cited and
acknowledged within the text of my work.
This thesis was prepared according to the regulations for
postgraduate study by research of the Dublin Institute of
Technology and has not been submitted in whole or in part
for an award in any other Institute or University.
The work reported on in this thesis conforms to the
principles and requirements of the Institute's guidelines for
ethics in research.

The Institute has permission to keep, to lend or to copy this
thesis in whole or in part, on condition that any such use of
the material of the thesis be duly acknowledged.

Signature___________________
Candidate

ii

Date _______________

Acknowledgements
I wish to express acknowledgement to Dr Patrick Goodman for his ongoing
support and advice and also to Dr Matt Hussey for his advice and suggestions.
Special thank you to Dr Patrick Manning for his encouragement and advice
throughout.

iii

Table of Contents
Page

Content
CHAPTER 1

Introduction

1

1.1

Background

1

1.2

An alternative end of test

3

1.3

Aims of thesis

5

1.4

Specific questions

5

1.5

Outline of thesis

6

1.6

Summary

7

1.7

References

8

Anatomy and Physiology of the Human
Respiratory System

10

2.1

Introduction

10

2.2

Anatomy of Respiratory System

10

2.2.1

12

CHAPTER 2

2.3

Nose, Pharynx and Larynx

2.2.2 Trachea

12

2.2.3 Bronchi, Bronchioles and alveoli

13

2.2.4 The lungs and Bronchial tree

13

Physiology of Respiration

15

2.3.1 Pressure Gradients

16

2.3.2 Resting breathing

17

2.3.3 Inspiration

18

2.3.4 Passive Expiration

19

iv

2.4

Summary

19

2.5

References

20

The Mechanics of breathing

22

3.1

Introduction

22

3.2

Airflow Patterns

23

3.3

Physics of airflow

23

3.4

Site of Airways Resistance

26

3.5

The Forced Expiratory Manoeuvre

29

3.6

Dynamic airway compression

31

3.6.1

32

CHAPTER 3

Tidal Breathing

3.6.2 Forced Breathing

33

3.6.3

Equal Pressure Point

34

3.6.4

Waterfall theory

36

3.6.5

Wave Speed Theory

36

3.7

Obstructive Ventilatory Pattern

37

3.8

Summary

38

3.9

References

39

Spirometric parameters and
Flow volume curves

41

4.1

Introduction

41

4.2

The evolution of spirometry measurements

42

4.3

Spirometer Devices

47

4.3.1 Introduction

47

4.3.2 Mass Flow Sensor

48

CHAPTER 4

v

4.4

Indications for Spirometry Testing

49

4.5

Measurement Technique

51

4.6

Measurement Variability

53

4.7

Spirometric Parameters

54

4.7.1

Vital Capacity, Forced Vital capacity

55

4.7.2

Forced Expiratory Volume at (t) seconds

55

4.7.3

Ratio of Expired Volume to Flow

56

4.7.4

Forced Average Expiratory Flow
as a percentage of FVC

56

4.7.5

Peak Expiratory Flow

56

4.7.6 Forced Expiratory Time

56

4.8

Expiratory Flow volume curves

58

4.9

Interpretation

60

4.9.1

Reference Equations

61

4.9.2

Defining Normality

63

4.9.3

Defining Airways Obstruction using
Lower Limits of Normal.

65

4.10

Summary

66

4.11

References

67

Literature Review

72

5.1

Introduction

72

5.2

Background

72

5.3

Studies into an alternative end of test point

73

5.4

Summary

80

CHAPTER 5

vi

References

81

Methodology

85

6.1

Introduction

85

6.2

Section A

86

5.5

CHAPTER 6

The spirometric findings of smokers compared
to non-smokers.
6.3

Section B

88

A comparison of FEV1/FEV6 to FEV1/FVC
in diagnosing airways obstruction
6.4

Section C

92

FEV1/FEV6 as a substitute for FEV1/FVC
in a subgroup of elderly patients using two
sets of reference equations
6.5

Summary

92

6.6

References

93

Results and Discussion

94

7.1

Introduction

94

7.2

Section A: The spirometric findings of smokers
compared to non-smokers.

95

7.2.1

Aim of study

95

7.2.2

Results

95

7.2.3

Discussion

100

7.2.4

Summary

104

CHAPTER 7

7.3

7.2.5 Hypostasis

104

Section B: A comparison of FEV1/FEV6 to
FEV1/FVC in diagnosing airways obstruction.

105

vii

7.4

7.5

7.6

7.7

7.3.1

Aim of study

105

7.3.2

Results

105

7.3.3

Discussion

107

Study B1: The effects of age on FEV1/FEV6
and FEV1/FVC ratios.

108

7.4.1

Aim of study

108

7.4.2

Results

108

7.4.3

Discussion

109

7.4.4

Summary

112

Study B2: The effects of the degree of
airway patency on the FEV1/FEV6 and
the FEV1/FVC ratios

113

7.5.1

Aim of study

113

7.5.2

Results

113

7.5.3

Discussion

115

7.5.4

Summary

117

Study B3: A comparison of FEV1/FEV6 to
FEV1/FVC in diagnosing airways obstruction.

118

7.6.1

Aim of study

118

7.6.2

Results

118

7.6.3

Discussion

119

7.6.4

Summary

122

Section C: FEV1/FEV6 as a substitute for
123
FEV1/FVC in a subgroup of elderly patients using
two sets of reference equations

viii

7.8

7.7.1

Aim of study

123

7.7.2

Results

123

7.7.3

Discussion

127

7.7.4

Summary

130

References

131

Conclusions

140

8.1

Summary

142

8.2

Further Work

143

CHAPTER 8

APPENDIX

144

ix

x

CHAPTER 1

1.1

INTRODUCTION

BACKGROUND
Lung Function testing has been available as a widespread diagnostic test in the

hospital setting for over 70 years. The term lung function is a collective name for a
group of physiological tests that are designed to objectively assess a particular part or
process of respiration. The advent of computerised analysis coupled with the
standardisation of both equipment and testing procedures have helped to secure lung
function testing an important place in the field of medical diagnostics.
The primary test of lung function is called spirometry; its name comes from the Latin
word ‘spirare’ (to breathe) and the Greek word ‘metron’ meaning to measure. In a
spirometry test a subject is instructed in a series of very energetic breathing manoeuvres
designed to objectively assess the flow and volume of exhaled air. The test is carried out
using equipment known as a spirometer. The spirometer records exhaled air volume,
and produces graphic and numeric information in the form of spirometric parameters
and tracings that can depict and describe the mechanical properties of the lung. These
spirometry values give a snapshot into how the lungs are functioning mechanically just
as a blood pressure measurement gives a quick and painless indication of a patient’s
cardiovascular status. The advantage of spirometry over other tests of lung function is in
its simplicity and the fact that it can be performed as a stand alone test without the need
for complicated computer software packages and gas analysis. It is also non-invasive
and if performed and interpreted correctly spirometry has the potential to be a very
effective screening tool for general lung health and in particular airflow limitation1.
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The measurement of the maximal volume of gas expired from the lungs is called the
forced vital capacity (FVC) (expressed as a function of time) and the measurement of
the maximum flow expired after 1 second of forced expiration is called the forced
expiratory volume in 1 second (FEV1). A spirometry test can be helpful in detecting the
presence or absence of a condition associated with airflow limitation. Airflow limitation
is defined as a ‘disproportionate reduction of maximal airflow from the lung in relation
to the maximal volume that can be displaced’2. The degree to which the airways are
limited or ‘obstructed’ can be determined by the ratio of FEV1 to FVC i.e. (FEV1/FVC).
When the airways are obstructed, for example in an individual with asthma, the airway
walls contract and so reduce the flow of air passing through them. Flow is often reduced
out of proportion to the volume that can be exhaled and hence the ratio of FEV1 to FVC
is reduced. To determine if a measured value is normal or abnormal it is compared to its
equivalent ‘reference’ value. Reference values are values obtained from regression
equations that have been calculated from the average values of a representative healthy
population. Reference values are dealt with in more detail in chapter 3.
Spirometry has been found to be an invaluable tool for the detection and management of
lung disease and for this reason, spirometric parameters are used extensively for
defining and categorising airflow limitation 3.
Airflow limitation is the main characteristic of chronic obstructive pulmonary disease
(COPD), a disease which is a major source of mortality and morbidity worldwide and
which is projected to become the third leading cause of death in the world by 20204.
COPD is an umbrella term that encompasses lung diseases which exhibit airflow
limitation and includes asthma, chronic bronchitis, and emphysema. It is a preventable
and treatable disease. Cigarette smoking is a major risk factor in the development of
COPD5. However, in many smokers COPD can go undetected for many years, causing
progressive loss of lung function at an accelerated rate. Population studies have shown
2

that simple spirometry testing can identify subjects at risk for undergoing accelerated
lung function loss and can offer a valuable opportunity to identify individuals at risk of
developing COPD by detecting airflow limitation in its early stages6,7. In two large
European studies, spirometry was found to be the key indicator of an accurate diagnosis
of COPD in the primary care setting by general practitioners8,9. Apart from its merits as
a screening test for airflow limitation, spirometry is also a major independent and
indirect predictor of cardiovascular morbidity and mortality10.

1.2

AN ALTERNATIVE END OF TEST TO THE FVC

The forced vital capacity (FVC) measurement is at the core of a spirometry test but it
possesses an inbuilt variability in its primary measurement, lung capacity. All other
spirometric indices are calculated from this capacity and therefore the ability to measure
this parameter accurately is critical to achieving a successful test. Reproducibility of the
FVC manoeuvre depends entirely on patient effort and co-operation; this requires that
rigid guidelines be in place for determining an acceptable and reproducible test. The
guideline that determines when a manoeuvre is complete and hence an accurate
determination of expired volume is called the ‘end of test’ criterion. Current guidelines
for the standardisation of spirometry testing in adults require a subject to inspire to
maximal volume and then expel with both speed and force for at least six seconds or
until no more than 25 millilitres (mls) of air are expelled over a period of 1 second. For
reproducibility this manoeuvre is required to be repeated three times in succession with
the goal of achieving two capacities within 150 mls of each other11.
This end of test criterion is in turn dependant on the time taken to forcefully exhale all
the air from the lungs, called the forced expiratory time (FET) which usually varies
from subject to subject.
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The majority of adults without airways disease have an average forced expiratory time
of between six and seven seconds. In elderly subjects and subjects with airflow
limitation, expiratory times are prolonged. The spirometry manoeuvre can then become
physically exhausting to the patient as expiratory times stretch out in some cases for as
long as 20 seconds, without adding much more additional clinical information. During
a testing session if the end of test criterion cannot be achieved the measurement is
judged to be unacceptable and the manoeuvre is repeated. In the clinical setting it is not
unusual to have patients with prolonged expiratory times that extend beyond 10 seconds
and patients are frequently encouraged to continue expiring until the end of test criterion
is satisfied. This can make the test unacceptable to the patient.
In response to the need for an alternative end of test criterion, a forced expiratory
manoeuvre of a duration that could be easily attained by the majority of adults has been
researched in recent times. This has led to the suggestion of a forced expiratory
manoeuvre based on six seconds duration, FEV6, as a surrogate for FVC. A shorter
manoeuvre such as FEV6 has the potential of reducing the burden of the test for the
patient and lowering the overall testing time. It also has the potential of improving
interpretation by reducing the variability of the volume measurement and making it
statistically more accurate when compared with reference values for the same
measurement. Ideally this surrogate measurement should at least retain the diagnostic
capabilities of the traditional FVC manoeuvre.
Figure 1.1 represents a graphical description of the FVC manoeuvre called a spirogram
which is a plot of exhaled volume against time. Spirometry tracings will be covered in
more detail in chapter 3. This shows the FVC and the FEV6 end of test point in a subject
with a prolonged forced expiratory time.
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FIGURE 1.1 SPIROGRAM DEPICTING BOTH FVC AND FEV6 END OF TEST POINTS1

1.3

AIMS OF THESIS

The main aims of this research thesis are to assess the utility of the FEV6 manoeuvre in
patients undergoing spirometry testing and in particular to determine if spirometric
indices measured at six seconds are clinically useful in pulmonary function, especially
in screening for early lung disease in smokers with an otherwise normal spirometry
pattern.

SPECIFIC QUESTIONS
The main questions this thesis seeks to answer are:
1. Are FEV6 and FEV1/FEV6 as or more clinically useful as the gold standard FEV1
and FEV1/FVC?
2. In our patient population can FEV6, FEV1/FEV6 be used instead of FVC and
FEV1/FVC without surrendering relevant diagnostic information?

5

3. In older individuals where expiratory times are naturally longer, does the FEV6
parameter diagnose airflow limitation as accurately as the FVC parameter using
specific reference equations for this age group?

OUTLINE OF THESIS
Chapter 2 gives an overview of the anatomy of the human respiratory system, and a
brief description of the mechanisms involved in resting breathing. This chapter serves to
provide a basic understanding of the mechanics of forced expiration which will be
discussed along with the mechanics of airflow in Chapter 3.

Chapter 3 looks at the physics of airflow and introduces the concept of airflow
limitation. Sections on the physiology of the forced expiratory manoeuvre and a brief
description of dynamic airway compression provide an introduction to the differences
that exist between obstructed and normal airflow.

Chapter 4 details the history of spirometry measurements, defines its parameters,
introduces the equipment used to measure spirometry and outlines the guidelines and
limitations associated with spirometry testing.

Chapter 5 gives an overview of published research to date on the FEV6 parameter.

Chapter 6 is a short overview of the methodology and the statistical analysis used in
this study.

Chapter 7 is a presentation and discussion of the results from each of the three studies
designed to answer the questions posed by this research.
6

Chapter 8 gives a brief summary of the conclusions arrived at in this thesis and
suggestions for further research into this topic.

1.6 SUMMARY
A shorter spirometry test manoeuvre that is easier for the patient to perform and that has
the potential to increase the accuracy of the test by minimising measurement variability
is an attractive feature for any diagnostic test. This is especially true for one that may
have a future in screening for early COPD in at risk subjects such as smokers. An
essential requirement of this possible surrogate test is that it at least upholds the
diagnostic ability of the traditional spirometry manoeuvre. This will be investigated
retrospectively in a patient population in this research.
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CHAPTER 2

2.1

ANATOMY AND PHYSIOLOGY
HUMAN RESPIRATORY SYSTEM

OF

THE

INTRODUCTION

This chapter gives a brief outline of the anatomy and physiology of the respiratory
system. The respiratory system made up of a group of interlinking components; each
component has its own unique structure, which serves to underlie its function. If any
one of the components is affected by disease this will impact negatively on the system
as a whole. The respiratory system has close links with the circulatory system of the
human body, both work together as pumps to maintain a steady state within the body.
The respiratory system grows as the body changes from birth to old age and also adapts
to the many challenges that comes its way from the simple increase in ventilation
required to facilitate exercise to the complex response to disease. This chapter aims to
introduce the various structures of the respiratory system and give a brief description of
their function.

2.2

ANATOMY OF THE RESPIRATORY SYSTEM

The main function of the respiratory system is to facilitate gas exchange. The
respiratory system is divided into two components the upper respiratory tract and the
lower respiratory tract1. The upper respiratory tract includes the nose, mouth, pharynx
and larynx. The lower respiratory tract consists of the trachea, bronchi, bronchioles and
alveoli. Each component of the respiratory system has a role to play in gas exchange.
Gas exchange occurs when air rich in oxygen is inhaled into the lungs through the nose
conducted through the respiratory system to the gas exchange areas of the lungs, called
alveoli. Gas exchange occurs at this point and the carbon dioxide that is not wanted by
the system is then expelled through the same pathway in the exhaled air.
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The anatomy of the lung lends itself to carrying out gas exchange as efficiently and
effectively as possible by providing a clear pathway from atmosphere to alveoli. The
airways connect the alveoli with the outside world, and play a pivotal role in the
understanding of lung function in health and disease. Figure 2.1 shows the anatomy of
the lungs.

Primary bronc:N
•
Seconclory ~onchl
CJ Bronchlotea
•
Rup/tlltory bronc:tololea

Left Lung

Left primary
bronchus

Right Lung

Left secon<lary

~;?;=:;:;;:::.=.-~-- bronchus
"".i~~~F-::--1r-

lobe

Left bronchiole

Bronchioles

FIGURE 2.1

ANATOMY OF THE HUMAN LUNGS1
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2.2.1 THE NOSE, PHARYNX AND LARYNX
Air enters the respiratory tract through the nose and the mouth. Normal
breathing occurs through the nose which has the advantage over mouth breathing in that
nasal respiratory mucosa serves to humidify and filter the incoming air. In this mucosa
are cells and glands lining the nose which secrete mucous to trap particulate matter and
tiny course hairs which propel trapped particles towards the pharynx. The term pharynx
comes from the Greek word meaning ‘throat’; it is a passageway for both air and food
and is connected to the voice box or larynx. The primary function of the larynx is to
prevent swallowed material entering the respiratory tract and it is also responsible for
speech2.

2.2.2 TRACHEA
The trachea is approximately 11-13 centimetres long in adults3 and is essentially
a tube that is prevented from collapsing by c-shaped rings of cartilage that surround it.
As shown in figure 2.2 the trachea is lined with ciliated pseudostratified columnar
epithelium and goblet cells, which trap and remove debris before reaching the lungs.

FIGURE 2.2

CELLS OF MUCOSAL LINING OF TRACHEA2
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2.2.3 BRONCHI, BRONCHIOLES AND ALVEOLI
The trachea divides into two main branches called primary bronchi, left and
right for each lung. The bronchi, just like the trachea, contain cartilage rings in their
walls which allow for physical support. Each primary bronchus divides repeatedly in
each lung giving rise to smaller branches called bronchioles which in turn subdivide
into tiny microscopic branches called respiratory bronchioles. The respiratory
bronchioles terminate into tiny saclike structures called alveoli where gas exchange
occurs. A dense network of capillaries to maximise gas exchange surrounds each
alveolus. There are approximately 400 million alveoli in each adult lung, and this figure
is closely related to a persons total lung volume, that is larger lungs have been found to
contain more alveoli4.

2.2.4 THE LUNGS AND BRONCHIAL TREE
The lungs lie in what is known as the thoracic or chest cavity, a rigid but
expandable structure that protects the delicate organs contained within it5. The two
lungs are separated from each other by a mass of tissues known as the mediastinum.
Each lung has an apex or upper part which is located about one inch from the clavicle,
and a base or lower part that rests above the principal muscle of respiration called the
diaphragm. The right lung has three lobes (upper, middle and lower) while the left lung
has an upper and middle lobe with an appendage of the upper lobe called the lingual. A
membrane called the pleural membrane surrounds each lung and consists of an inner
layer called the visceral pleura and an outer layer covering the ribcage called the parietal
pleura. These pleural layers are shown in figure 2.3.
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FIGURE 2.3

PLEURAL CAVITIES OF THE LUNG3

The space between these two layers is called the intrapleural cavity, and it contains a
small amount of pleural fluid allowing lubrication of the membranes preventing friction
during breathing. The intrapleural cavity or space plays a pivotal role in how the lungs
inflate and deflate.
The geometry of the airways is analogous to a branching tree turned upside down.
Where the tree first starts to branch at the trachea is referred to as generation zero and
each set of branching thereafter gives rise to a new generation resulting in twenty-three
generations in total6. Figure 2.4 shows the generation of branching from trachea to
alveoli. The first sixteen generations are collectively referred to as the conducting
airways, the remaining seven generations, which occupy most of the lung, are referred
to as the respiratory zone and this is where gas exchange occurs.
As each branch subdivides the radius of that branch is reduced and as the branches get
smaller the total cross sectional area rapidly increases. The function of such a huge
increase in cross sectional area is to maximise the potential for gas exchange by making
14

sure that as much surface area as possible is available for the diffusion of gas across the
blood gas barrier. The blood gas barrier itself is extremely thin, approximately 0.3 μm,
and its surface area is enormous, approximately 50-100 square meters7.

FIGURE 2.4

2.3

GENERATION OF AIRWAYS FROM TRACHEA TO ALVEOLAR
LEVEL4

PHYSIOLOGY OF RESPIRATION
While the primary function of the lung is to facilitate oxygen and carbon dioxide

gas exchange, the chest muscles also play a major role in the mechanism behind
breathing. The main respiratory muscles used are the diaphragm and the external
intercostals. The diaphragm is a big dome shaped muscle that lies at the base of the
lungs and when it contracts as it does during inspiration, it straightens out and in doing
so increases the thoracic cavity volume. As in Figure 2.5 the external intercostals are
located between the ribs and on contraction they have the power to pull the ribs up and
in doing so push the sternum forward increasing the diameter of the thorax. The muscles
used for expiration are called the internal intercostals and the abdominal muscles. As
expiration does not actively involve muscle contraction it is referred to as a passive
motion. Normally the expiratory muscles are only called on during the laboured
breathing that accompanies strenuous exercise. However, in subjects with obstructive
ventilatory diseases such as COPD, these muscles may be called on early in an
expiratory effort for assistance.
15

FIGURE 2.5

MUSCLES OF
ABDOMEN5

THE

THORACIC

CAGE

AND

ANTERIOR

2.3.1 PRESSURE GRADIENTS
The lungs can be looked upon as elastic structures contained in a chest cage that is
expandable. The lungs have inward recoil that is directly balanced by the outward recoil
of the chest wall. Breathing requires continuous movement of the lungs to and from
their resting position. Initiation of breathing requires that a pressure called the elastic
inward recoil pressure (PL) of the lung is overcome. The ability of the lungs to
overcome this pressure and expand and contract in a normal breathing motion relies on
many factors working together, both inside and outside of the lungs8. Factors underlying
the generation of airflow involve the behaviour of pressure differences in the respiratory
system enabling the breathing process and preventing the lungs collapsing on
expiration. During resting breathing air moves into the lungs by bulk gas flow from an
area of higher pressure outside the lung to an area of lower pressure within the lung.
The pressure outside the lungs called the atmosphere pressure (Patm) is higher than the
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pressure contained in the alveoli called alveolar pressure (Palv) and so air will be
automatically drawn into the lungs.
The opposite will occur when pressure in the alveoli is greater than that of the
atmosphere and air will automatically leave the lungs on expiration. Between breaths,
alveoli and atmospheric pressure are equal and no flow exists. There is a tension in the
thorax between the lungs trying to collapse and the chest wall trying to spring out. As
mentioned in section 2.2.4 the space between the chest wall and the lungs is called the
intra pleural space. This space has its own pressure called the intra pleural pressure
(Ppl) which serves to balance the two opposing forces and prevents the lungs from
collapsing. At any given time the Ppl is negative with respect to Patm, and negative
with respect to Palv, because the Palv are connected to the atmosphere by the branching
airways.
2.3.2 RESTING (BETWEEN BREATHS)
Figure 2.6 depicts the pressure gradients of the lung before inspiration begins.

FIGURE 2.6

PRESSURE GRADIENTS OF THE LUNG BETWEEN BREATHS6
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Just before inspiration, Patm is equal to Palv and as the pressure is zero in the airways
no air flow occurs and the diaphragm is in a relaxed position. The lungs remain inflated
due to the Ppl remaining at a lower pressure than the pressure contained in the alveoli.
Thus the airways remain patent as the negative intrapleural pressure is balanced by a
positive pressure of the same magnitude holding the airway open.

2.3.3

INSPIRATION (BREATHING IN)

On inspiration, the muscles contract, expanding the rib cage and the attached pleural
membrane and thus widening the intrapleural space and lowering its pressure. This
difference in pressure or pressure gradient between intrapleural and alveolar regions
pushes the lung wall outwards and the lungs expand increasing alveolar space and
lowering the pressure there. When Palv is lower than Patm air will flow into the lungs.
Figure 2.7 depicts the pressure gradients existing in the lung at inspiration. As
inspiration begins both the intrapleural and the alveolar pressure fall and air flows into
the lungs.

FIGURE 2.7

PRESSURE GRADIENTS OF THE LUNG ON INSPIRATION6
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2.3.4

PASSIVE EXPIRATION (BREATHING OUT)

On passive expiration, the diaphragm and the intercostal muscles relax allowing the
lung to recoil. After inspiration there is additional air in the lungs, which causes Palv to
be greater than Patm thus causing bulk gas flow out of the lungs. Figure 2.8 depicts the
pressure gradients existing in the lung at passive expiration.

FIGURE 2.8

2.4

PRESSURE GRADIENTSOF THE LUNG ON PASSIVE EXPIRATION6

SUMMARY

This chapter briefly outlined the anatomy and physiology of the human respiratory
system. A section on the respiratory muscles used in breathing and a brief description of
the mechanisms involved in normal breathing serve to provide a basic understanding to
the mechanics underlying forced expiration which will be discussed along with the
physics of airflow in Chapter 3.
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CHAPTER 3

3.1

THE MECHANICS OF BREATHING

INTRODUCTION

Air in its journey from atmosphere to alveoli will experience an opposition to flow due
to frictional resistance. The amount of resistance will depend on the linear velocity of
the airflow which will in turn be affected by the airflow pattern and its location within
the bronchial tree1. The nature and site of this resistance and the behaviour of airflow
when it encounters the resistance gives an insight into how airways disease can have
significant effects on lung function. The use of the forced expiratory volume at six
seconds (FEV6) to determine airways obstruction accurately and reproducibly through
spirometry testing is a key focus of this thesis and so this chapter will concentrate on the
physiology behind the flow volume curve generated during a spirometry measurement.
The first section of this chapter serves to introduce the concepts of airways resistance
(RAW), the pattern of airflow, and the site of resistance. The second section will
concentrate on the physics of airflow within the branches of the respiratory system. The
final section details the physiology behind the spirometry manoeuvre and introduces the
concept of airways obstruction from a physiological viewpoint. Tests of forced
expiration reflect the mechanical workings of the lung. The physiological factors that
determine maximal expiratory flow include the elastic properties of the lung, airways
resistance and dynamic compression of the airways2. How these factors interact in
healthy lungs provides the basis for understanding how disease affects lung function,
allowing a better understanding of patterns of dysfunction that spirometry testing reveal.
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3.2

AIRFLOW PATTERNS

There are three main patterns of airflow that exist in the bronchial tree, laminar,
turbulent, and transitional. Laminar flow is smooth, parallel airflow and can be found in
smaller airways where the rate of airflow is slow. Turbulent flow as its name suggests,
is a flow pattern that may be forward flow but unlike laminar flow it is non-parallel and
non-linear. Turbulent flow occurs mainly in the large airways. The mixture of these two
flow patterns, referred to as transitional flow, is most likely to exist at airway branch
points. Figure 3.1 shows the various airflow patterns which occur within the human
airways.

FIGURE 3.1

3.3

AIRFLOW PATTERNS1

PHYSICS OF AIRFLOW

In order to understand the nature and contribution of frictional resistance encountered
by air as it makes its way from atmosphere to alveoli, two relationships are used, the
analogy to Ohm’s law and Poiseuille’s equation. The airways are analogous to an open
tube, and as seen in figure 3.2 airflow occurs when there is a pressure difference
between both ends of the tube P1 and P2.
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Ohm’s law for an electric circuit states that current is equal to voltage divided by
resistance, and the equation reads:
I = V/R

Equation 3.1

where V = Voltage, I = Current and R = Resistance.
Applying by analogy, Ohm’s law to conditions existing in the airways, the equation can
be rearranged as follows R = V/I, and the airways resistance RAW then becomes:
RAW= ∆P/V

Equation 3.2

where ∆P=P1-P2, the difference in pressure from P1 to P2.

FIGURE 3.2

AIR FLOW IN THE HUMAN AIRWAYS UNDER PRESSURE DIFFERENCE1

The resistance RAW to airflow is obtained by dividing the pressure difference in the
airway by the airflow rate V. Two variables considered in Ohm’s law are pressure and
flow rate. Building on this a French physicist, Poiseuille, developed an equation to
describe airways resistance through a tube in terms of the physical dimensions of the
tube and the nature of the fluid moving through it (Figure 3.3) thus,

RAW= 8ηl / πr4

Equation 3.3

where r = radius of tube , η = viscosity of flowing substance, l = length of tube,
π = 3.14
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FIGURE 3.3

ILLUSTRATION OF POISEUILLE’S DESCRIPTION OF LAMINAR
AIRFLOW APPLIED TO THE HUMAN AIRWAYS1

Poiseuille’s equation states that the frictional resistance to flow is directly related to
viscosity of the air and the length of the tube and indirectly related to the fourth power
of the tube radius. According to Poiseuille’s equation the radius of the tube is critical in
determining the magnitude of airways resistance. If the radius of the tube is reduced by
approximately 50% with no change to either tube length or the viscosity of the air
flowing through it, the calculated resistance would increase by sixteen-fold, or the
driving pressure would need to increase by sixteen-fold to maintain the same flow.
However unlike Poiseuille’s equation, which was derived using rigid smooth tubes that
encourage a laminar flow pattern, the human airways are distensible and have
continuously branching tubes of various radii, where both laminar and turbulent flow
co-exist. The transition from laminar to turbulent flow can be indicated by a number
called the Reynolds’ number.
Reynolds’ number = vd/ η

Equation

3.4

where  = density of fluid, v = linear velocity, 2r = diameter of tube, η = viscosity of
fluid
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The size of the Reynolds’ number will to a large extent determine whether flow in a
particular branch will be laminar or turbulent. Turbulence occurs when the Reynolds’
number is very large, something in the magnitude of 2000, when the velocity of flow is
high and the tube diameter is large, for example at the trachea. In the smallest of
branches, the terminal bronchioles, Reynolds’ number is approximately 1 and this
dictates that the type of airflow there will be laminar. For the majority of the bronchial
tree, flow is transitional moving from areas of turbulence to areas of laminar flow 3.

3.4

SITE OF AIRWAYS RESISTANCE (RAW)

The nature and site of airways resistance is important in understanding the mechanism
behind lung disease as resistance to airflow is likely to be increased in certain lung
diseases4. As the bronchial tree subdivides and its branches become smaller and more
numerous, the diameter of the terminal bronchioles are many times smaller than the
diameter of the bronchi. As mentioned in chapter 2, section 2.2.4, each set of airway
branchings gives rise to a new generation resulting in twenty-three generations in total.
The fourth and eight order of branching include the medium sized bronchi. The eight to
twelfth generations include the bronchioles and generation sixteen onwards include the
terminal bronchioles. Figure 3.4(A) shows the position of airways resistance in relation
to the order of generation of branches in the bronchial tree and Figure 3.4 (B) shows the
relationship of linear velocity and cross sectional area through each generation of
branching.
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FIGURE 3.4 (A) SITE OF AIRWAYS RESISTANCE IN THE BRONCHIAL TREE2

FIGURE 3.4 (B) RELATIONSHIP OF LINEAR VELOCITY AND CROSS SECTIONAL AREA
IN THE BRONCHIAL TREE2
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According to Poiseuille’s equation (equation 3.3) the major site of airways resistance
should be in the location of the smallest airways with their small radii at generation
sixteen onwards. However, studies have shown this is not the case, but rather the
medium size airways have the greatest airways resistance5. Small airways (< 2 mm in
diameter) have the potential for greater airways resistance; however small airways
branch repeatedly and in doing so create a large cross sectional area for airflow. This
large cross sectional area dictates that flow in the small airways is slower and is laminar.
An analogy to electrical resistors can also be used to describe the behaviour of airways
resistance in the small airways. Like resistors in an electrical circuit, airways through
the generations of branching from the trachea to the bronchi to the bronchioles can be
described as being in series. Resistances in series are added to give the total resistance
(Rtot).
Rtot = R1 + R2 + ……..Rn

Equation

3.5

The total resistance of a given generation is greater in airways that exceed 2 mm (figure
3.4). When all the resistances of a generation are added together, the overall resistance
of that generation decreases, this occurs because these resistances are in parallel and the
total resistance is obtained from the inverse of the sum of the reciprocal of each
resistance
RTOT = 1/ 1/R1 +1/R2 +……… 1/Rn

Equation 3.6

1/RTOT = 1/R1 +1/R2+……1/Rn
The resistances arranged in parallel can be added as reciprocals of their individual
resistances therefore yielding a far less total RAW. This arrangement negates the effect
of a reduced diameter on the resistance. The first studies conducted to determine the site
of airways resistance was performed on dogs and later on humans using a catheter
inserted into the lungs in an attempt to bypass the large airways.
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These studies proved that small airways resistance was only a minor contributor to
overall resistance6. As the small airways have little resistance, airways disease can go
unnoticed for many years and this area is referred to as the ‘silent zone’ of early airways
disease.

3.5

FORCED EXPIRATORY MANOEUVRE

Expiration in normal breathing conditions is a passive process but when air is physically
expelled from the lungs the airways become compressed and close. This compression is
a natural phenomenon occurring only at very low lung volumes in young healthy
subjects. However disease of the respiratory system can cause this compression to be
exaggerated and to occur earlier in the forced expiration than would naturally occur in
healthy airways. This early compression is also apparent in the lungs of healthy elderly
subjects mainly due to the loss of elastic recoil that accompanies the natural ageing
process of the lungs7. The site and nature of airway compression can be measured
indirectly by performing a breathing manoeuvre called a forced expiratory test on
equipment known as a spirometer. The spirometer produces a graph called a flow
volume curve which provides visual evidence of the airway compression.
Spirometry testing requires a subject to inspire to a maximum volume called total lung
capacity (TLC) and then blow out very fast into a spirometer until a minimum volume is
reached called the residual volume. By ‘blasting’ the air out of the lungs a force is
applied to the thoracic cavity and lungs causing the pressure in the alveoli (Palv) to
increase well above atmospheric pressure (Patm), which results in air leaving the lungs.
Figure 3.5 depicts a typical flow volume curve produced from a forced expiratory
manoeuvre.
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FIGURE 3.5

FLOW VOLUME CURVE ON NON-DISEASED AIRWAYS3

Flow begins at zero and rises rapidly to a peak flow point, the curve declines over most
of the expiration as air is forced from large to medium to small airways until reaching a
zero volume. The shape of a flow volume curve is very reproducible for non-diseased
lungs but can be altered by airways disease in characteristic ways. This is due to a
mechanism known as dynamic airway compression or flow limitation.
The site and extent at which flow limitation occurs will ultimately determine the shape
of the flow volume curve. Section 3.7 will introduce the physiology behind the
mechanism of flow limitation and provide a brief summary of some of the theories used
to explain flow limitation.
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3.6

DYNAMIC AIRWAY COMPRESSION/ FLOW LIMITATION

Dynamic airway compression as its name suggests describes what happens to the
airways as air is physically forced out of the lungs with speed. The way in which the
airways respond to this dynamic compression is different in health and disease.
Spirometry testing has made it possible to understand the mechanical events that limit
maximal exhalation, and to locate with the aid of flow volume curves the location of
this dynamic compression.
In the build up to a forced expiration, a maximum breath is inhaled to TLC and in doing
so the ribcage is expanded allowing the lung to hold this maximum volume, and as the
lungs are now stretched the pleural pressure is at its maximum. The initial burst of air,
called the peak flow point is effort-dependent and produced entirely by expiratory
muscle force. Beyond the peak flow point the expiratory muscles fail to play a
significant role and elastic recoil takes over to maintain the expiratory flow. The change
from effort-dependent to effort-independent flow and the pressures that drive the flow at
this point is called flow limitation. There are three theories used to explain flow
limitation, the equal pressure point by Mead et al.8, the waterfall theory by Pride et al.9
and the wave speed theory of flow limitation by Dawson et al.10. A detailed description
of the equal pressure point followed by a brief summary of the waterfall and wave speed
theories of flow limitation follows.
As described in chapter 2 section 2.3.1, the normal breathing cycle is brought about by
changes in pressure gradients. Pressure gradients behave differently when air is forced
at speed from the airways and the following sections will describe this process.
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3.6.1

TIDAL BREATHING

Tidal breathing is the pattern of breathing performed unconsciously at rest. On average
a subject will inhale approximately 500ml of air with each tidal breath and exhale the
same amount. Before inspiration begins the respiratory muscles are at rest and the
elastic recoil of the lung (Pel) and the elastic recoil of the chest are equal but opposite
and the pressure inside the alveoli (Palv) is at the same pressure as the atmosphere
(Patm). As mentioned in chapter 2, section 2.3.1, a pressure gradient needs to exist
before air can flow, and air will only flow from an area of higher pressure to one of
lower pressure and since Palv = Patm there is no airflow. During inspiration the
diaphragm contracts and in doing so compresses the abdominal contents and
decompresses the contents of the thorax causing the pleural pressure to fall. As Ppl falls,
Palv falls by an equal amount becoming sub atmospheric and creating a pressure
gradient. Air flows into the lungs down the pressure gradient from mouth to alveoli. The
lungs and chest expand in volume, and this causes the recoil pressure of the lung to
increase until a new equilibrium is reached. Equilibrium exists after inspiration and
before expiration begins. Air flows down the pressure gradient until the lung reaches a
new equilibrium volume at which Palv equals zero and the gradient for flow ceases to
exist. Lung and chest wall are fully expanded.
During expiration the respiratory muscles relax, allowing the lung to recoil causing an
abrupt increase in Ppl to a less negative value. Additional air in the lungs causes the
Palv to rise above Patm and air flows out of the lungs. Lung volume and chest wall
dimension decrease as air flows out causing lung recoil pressure to fall until a new
equilibrium is reached. At end expiration, the pleural cavity and the alveoli return to the
pressure relationship they had at the start of inspiration.
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3.6.2

FORCED BREATHING

As detailed in Chapter 2, the lungs are elastic structures and they have an inbuilt
tendency to want to recoil, like a spring, a tendency called the elastic recoil pressure of
the lung (Pel). In the build-up to a forced expiratory manoeuvre, a deep breath is taken
into the lungs and they stretch, and as the lungs stretch, they have an even greater
tendency to want to spring back into the resting position. In order to overcome this
tendency and expand the lungs to their maximum, a pressure known as the
transpulmonary pressure (PLel) needs to be increased. The transpulmonary pressure is
the pressure difference across the lungs. At the start of a forced expiration Ppl rises very
steeply as the expiratory muscles contract and the lung volume decreases. The Palv
increases and forced expiratory flow begins. At this point a pressure gradient exists
from mouth to alveoli, and as flow occurs the pressure inside the airway becomes less
than the pressure outside the airway. The pressure falls steadily going from the alveoli
where it is high, falling steadily through the bronchi (Pbr) to the level of the mouth
(Pmo) and out into atmosphere (Patm). This pressure fall occurs because of the fall in
resistance that is greater towards the trachea where the number of parallel airways
decreases. In addition, the gas velocity increases towards the trachea, as the cross
sectional area of the airways decreases. As this exhalation continues, lung volume
decreases, causing a fall in the static recoil pressure which reduces the transpulmonary
pressure. Somewhere along the airway, the transmural pressure will become negative, as
Ppl will exceed the airway pressure, resulting in compression of the airways.
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FIGURE 3.6

CONDITIONS EXISTING IN THE RESPIRATORY SYSTEM DURING
FORCED EXPIRATION4

3.6.3 EQUAL PRESSURE POINT THEORY
By exhaling a full breath of air with maximal force, through a tube, as in a spirometry
test, a large force is applied to the thoracic cavity, causing both pleural pressure (Ppl)
and alveolar pressure (Palv) to increase well above atmospheric pressure. Then as flow
begins the pressure along the airways from the alveoli to the mouth drops and the
airways tend to compress and limit flow. Once the expiratory flow becomes limited, the
airways at the alveoli are distended whereas the airways at the trachea are compressed.
This led investigators to believe that there must be points between the trachea and the
alveoli where airways are neither compressed nor distended. Such points were then
called equal pressure points (EPP), where the pressure inside the airway had to be equal
to the pressure outside the airway. The airways could be then looked upon as two
separate segments, a distended segment and a compressed segment. At the EPP the
limiting flow becomes the pressure outside the airway called the intrapleural pressure or
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the elastic recoil pressure (Pel). This pressure is the driving pressure, and if a subject
tries to physically force the breath out at the end of expiration by using respiratory
muscles to increase intrapleural pressure further, this will have absolutely no affect on
the driving pressure, making flow independent of effort. The maximum flow expelled
however will decrease with decreasing lung volumes, because the difference between
alveolar and intrapleural pressure decreases as the airways narrow up to the EPP. As the
lungs empty the EPP moves into increasingly smaller airways and continues on until the
airways close, trapping some gas in the alveoli at a point known as the residual volume
of the lung.
This expiratory mechanism is called dynamic airway compression and is what gives the
characteristic linear or slightly concave shape to the maximum expiratory curve on the
spirometer tracing. The curve has a maximum flow/volume envelope that is remarkably
consistent even with variable expiratory efforts. Figure 3.7 shows a forced expiratory
tracing performed with various efforts and at various starting volumes.

FIGURE 3.7

MAXIMUM EXPIRATORY EFFORT CURVES WITH VARIABLE SUBJECT
EFFORT (A,B,C,D)5
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When the maximum flow volume envelope is reached the decline in expiratory flow as
the lung empties will always follow the same pathway regardless of the starting volume
or effort. For each point of the curve, a maximum flow cannot be exceeded regardless of
the effort exerted.

3.6.4

WATERFALL THEORY

Following from the equal pressure point theory, and in an effort to explain flow
limitation researchers modelled the lung as a resistance between the alveoli and a point
downstream from the EPP where transmural pressure reached a critical value that was
enough to limit flow. This is analogous to a waterfall, where flow is independent of the
height of the falls, just as maximal expiratory flow limitation is independent of the total
driving pressure between alveoli and mouth.9

3.6.5

WAVE SPEED THEORY

Dawson and Elliott10 showed that maximal expiratory flow occurs when the linear
velocity of gas at the flow limiting segments, which they termed choke points, becomes
equal to the speed at which a pressure wave travels along the airways to the alveoli.
This high linear velocity prevents transmission of downstream pressure through choke
points, so that flow becomes independent of pressure.
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3.7

OBSTRUCTIVE VENTILATORY PATTERN
Spirometry testing can reveal patterns in the form of numerical values and flow

volume curves that are typical of specific lung diseases. These patterns are used to make
judgements in clinical practice on the site and nature of the disease process within the
lung in conjunction with other clinical data. Airways disease can be broadly divided
into two main groups by the nature of their structural impairment termed obstructive
and restrictive ventilatory disorders. Obstructive disorders as their name suggests,
‘obstruct’ the flow of air out of the lungs causing an increase in airway resistance, and
included asthma, chronic bronchitis, emphysema and chronic obstructive pulmonary
disease (COPD). Restrictive lung disorders can affect the bellows action of the lungs
and chest wall by ‘restricting’ the process of inflation. Restrictive diseases include
thoracic wall deformity and pulmonary fibrosis. An obstructive ventilatory airflow
pattern typical of a subject with COPD produces a flow volume curve as shown in
figure 3.8. A normal curve is superimposed for comparison. In obstructive airways
disease the airway walls loose tension and become flaccid. During a forced expiratory
manoeuvre, the airways collapse and the equal pressure point occurs nearer the alveoli
than in healthy subjects producing a curve that has a ‘scooped’ out appearance.
Obstructive diseases are also likely to cause an increased resistance in the smaller
airways and an elastic recoil pressure occurring closer to the alveoli, which leads to
greater compression and greater airflow limitation11.
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FIGURE 3.8

FLOW VOLUME CURVE OF (A) SUBJECT WITH NO AIRWAYS DISEASE
AND
(B) SUBJECT WITH SEVERE AIRWAYS DISEASE6

3.8 SUMMARY
This chapter outlined the mechanics of airflow. Sections on the physiology of the forced
expiratory manoeuvre and a brief description of dynamic airway compression serve to
introduce an understanding of the differences that exist between obstructed and normal
airflow in terms of the site of airways resistance. The next chapter will deal with the
parameters measured from a spirometry test.
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CHAPTER

4.1

4.

SPIROMETRIC PARAMETERS
VOLUME CURVES

AND

FLOW

INTRODUCTION
The way in which the lungs behave mechanically differs in health and disease

and depending on the site and nature of the disease this difference can significantly
affect the lungs ability to perform its main function of gas exchange. An understanding
of the volume and flow rates of the lung is necessary in order to assess the degree of
lung impairment. Often in individuals with suspected lung disease, spirometry is the
first test used in the investigation stage. The values generated from a spirometry test
provide graphic and numeric information, which depict and describe the mechanical
properties of the lung, chest wall and respiratory muscles. Although the breathing
manoeuvre required for spirometry is far removed from a normal breathing pattern, the
results and graphs created are very reproducible for a given person, and can show
characteristic patterns of dysfunction in lung disease when present. Interpretation of
spirometry results involves comparison of measured values with ‘normal’ reference
values generated from a population of healthy individuals matched for age, height,
gender and ethnicity.
The equipment necessary to carry out this test is called a spirometer.
Spirometers come in various formats. Small portable stand-alone versions are
commonly used in clinics whereas more complex devices tend to be found in
specialised hospital-based lung function equipment. This chapter will focus on the
parameters and tracings produced from a spirometry test, and how these values are
interpreted. Section 4.2 will cover the evolution of the spirometry measurement. Section
4.3 details spirometer devices the principles behind the measurement and quality control
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in the measurements. A section describing how a spirometry measurement is performed
followed by a section on the various parameters and tracings associated with spirometry
testing. The interpretation of spirometry results and a section on reference values are
covered in the final section of this chapter.
4.2

THE EVOLUTION OF SPIROMETRY MEASUREMENTS

In 1846 an English surgeon John Hutchinson published in the Lancet journal the first
study of its kind documenting, measuring and advocating the importance of the
physiological measurement of lung function. Hutchinson invented a calibrated bell,
inverted in water, in order to be able to measure the volume of exhaled air from fully
inflated lungs.

This measurement he called the vital capacity (VC), meaning the

capacity to live, as he realised that compromise of vital capacity was predictive of
premature death. Hutchinson’s studies showed that vital capacity in normal healthy
subjects was directly related to standing height, and inversely related to the age of the
individual. He also observed that vital capacity became mildly reduced following a
large meal. In his first article published in 1846, he reported on the measurement on
2,130 individuals, including deceased patients. Hutchinson would go to the morgue
immediately following death and insert into the trachea the equivalent of an
endotracheal tube with a stopcock, and inflate the corpse with a bellows until no more
air could enter. He then released the flow of air into his spirometer, observing that the
lungs and thorax emptied under elastic recoil to a minimum volume called the residual
volume. Hutchinson became a consultant to the insurance industry of London,
advocating the need for spirometry measurements of vital capacity to be used in
actuarial predictions for life insurance brokers. However, Hutchinson’s spirometer was
not widely accepted in London and at the age of 41 he emigrated to Melbourne,
Australia where all further use of the spirometer was abandoned. Hutchinson spent his
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final years on the island of Fiji, where a statue was erected in his memory by the
Thoracic Society of Australia and the British Thoracic Association in 1990 1,2,3,4,5,6

FIGURE 4.1

SILHOUTTE OF JOHN HUTCHINSON AND HIS SPIROMETER1

Hutchinson’s research introduced to the world the first water-sealed type of spirometer
which some aspects are still evident in today’s devices. It was not until the 1940 s that
the concept of measuring the rate of volume exhaled was introduced, born from the
observation that individuals with asthma, emphysema, chronic bronchitis and other such
obstructive ventilatory disorders, exhaled at a slower rate than healthy individuals. The
forced expiratory volume (FEV) was first described by Tiffeneau and Pinelli7 working
in Paris, in December 1947, more than 100 years after the first measurement of lung
function was made by Hutchinson. In those 100 years, spirometry had been considered
an important tool but could not be utilised fully, mainly because the technology was not
sufficiently sensitive to measure instantaneous flow. A more precise evaluation of the
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dynamic behaviour of the lungs only became possible after the description of the
pneumotachograph by Fleisch8 in 1925.
Soon afterwards, Engelmann10 noticed that asthma was characterised by a
marked prolongation of the expiratory phase, and after epinephrine was administered to
the patient, a normal expiratory phase was observed. Hermannsen11 was the first to
record the maximal ventilatory possibilities during a sustained voluntary effort in 1933,
after this several investigators started to relate the sensation of dyspnoea to the
maximum breathing capacity (MBC). A study published in 1938 by Barrack12 computed
the expiratory and inspiratory flow, and expressed them in cubic centimetres per second.
This concept gave a greater insight into the patency of the airways and equipped the
spirometer with a rotating drum, where volume changes could be recorded as a function
of time. Gambits13 also in 1938 realized that the level of maximum breathing capacity
MBC is determined by the size of the vital capacity (VC). He proposed to use the ratio
MBC (l/min)/ VC (l), subsequently called the capacity ratio, and nowadays referred to
the FEV1/VC ratio. Courante et al.14 observed a striking decrease in the rate of
expiration in patients diagnosed with emphysema.
Other studies at this time showed that the time necessary for a full maximal
expiration was markedly different for normal subjects compared to patients with
obstructive ventilatory diseases, for whom forced expiratory times were prolonged. Cara
et al.15specified that a subject must breathe out as quickly, strongly, and completely as
possible, during a forced expiratory manoeuvre, and that correction factors for
barometric pressure and temperature must be considered and applied to the
measurement for accurate and reliable recordings to be made. Tiffeneau’s group16 made
several more important observations which are still largely valid today; they had noticed
that during exercise both the circulating air or tidal volume and the respiratory
frequency tend to increase. They proposed to measure the maximal volume that can be
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expired in a space of time corresponding to the usual duration of an expiratory phase
during exercise. They called this measurement the “capacitē pulmonaire utilisable a
l’effort” (CPUE). The CPUE was proposed to be equal to the largest volume that can be
expired in one second. This is now known as the forced expiratory volume in one
second FEV1.
Despite these observations and studies, the contribution of these French investigators
remained largely ignored. A group of respiratory investigators in the US met in April
1950 to standardise the definitions and symbols used in respiratory physiology. In the
US, at this time, it was Gaensler’s work17on the analysis of the forced expiratory
volume that was fast becoming accepted. Gaensler’s adaptation of the water-sealed
spirometer using a micro switch to time the forced expiratory breath, meant that for the
first time airway obstruction could be assessed. He proposed to calculate air velocity
index (AVI) and made measurements in 435 patients. In 23 normal patients he found an
AVI above 1, and similar results after a lobectomy. However in 36 asthmatics the AVI
was reduced. He also noted that the slope of the expiratory tracings was very steep
during the first seconds, and that an accurate measurement of the volume of air could
not be made. He adapted the spirometer to introduce a time element, and thus the timed
VC was born.
Gaensler’s studies concluded that a healthy individual could exhale approximately 80%
of their capacity in the first second of a forced expiratory blow. Any forced expiratory
measurement falling short of this critical measurement could be interpreted as indicating
the presence of airways obstruction.
The timed VC then started to gain more popularity over the MBC. Fowler et al.18
provided evidence that there was no initial period of sustained constant flow rate, except
occasionally in normal persons during somewhat sub-maximal effort.
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The acceleration of the airflow during the first several tenths of a second was, in fact, so
large that an accurate recording of this portion of the trace with a spirometer was
considered uncertain. Therefore, they advocated measurement of the average flow over
the middle of a rapid maximal expiration: the maximal mid-expiratory flow rate was
born. They demonstrated a graphical method to assess airway obstruction, and were the
first to measure and document the parameter FEF25-75% that is the mid section of the
forced expiratory tracing. This and other parameters were used with more confidence to
differentiate healthy airflow from obstructed airflow. Ten years after his first work on
the subject, Tiffeneau published his monograph summarising all his work on the
VEMS, the “volume expiratoire maximum seconde”, the term that superseded the
CPUE

19

. The British Thoracic Society adopted recommendations on terminology for

measurements of ventilatory capacity they replaced the term ‘timed VC’ with the
expression we know today as the ‘forced expiratory volume over a stated interval of
time’ and hence the FEV1 and FEV3 and FEV6. The nomenclature accepted today is the
VEMS in French and the FEV1 in English. After over 50 years, the VEMS and the
FEV1 have become used daily by respiratory physiologists and physicians to measure
and document respiratory disease.
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4.3

SPIROMETER DEVICES

4.3.1 INTRODUCTION
Spirometer devices are specifically designed to collect measure and display exhaled
flow and volume. There are two types of spirometer, volume displacement and flow
sensing. In a volume displacement spirometer exhaled volume is the primary signal and
flow is obtained from differentiation of volume with respect to time. A flow sensing
spirometer will measure flow directly and then integrate this signal to obtain a volume
measurement. Regardless of the type of spirometer used it must conform to a set of
specific standards as recommended by the joint working parties of the European
Respiratory Society (ERS) and the American Thoracic Society (ATS) 3 (Appendix A).
Conformity of equipment has led to a major reduction in the measurement
variability that was previously witnessed between spirometers, but the requirement for
accurate and reproducible measurements is still the responsibility of the individual
providing the spirometry service16. Maintaining high standards of accuracy require that
a robust quality control (QC) system is in place. Instrument quality control involves two
related procedures called calibration and quality control-checks. Calibration is the
procedure for establishing the relationship between spirometer-determined values of
flow and volume and actual flow and volume. A quality control check is the procedure
used to validate that the spirometer is within its calibration limits.
The modern spirometer is a lightweight portable medical device with a built-in
microprocessor that can store and display many parameters, print tracings and even
offer a computerised interpretation based on algorithms. Despite the many advances in
medical technology, the underlying principle and the measurement of spirometry stay
true to the original volume displacement spirometer introduced to the world by
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Hutchinson more than a century ago. The type of spirometer used to produce the results
in this research thesis is a flow-sensing anemometer type known as a mass flow sensor.

4.3.2

MASS FLOW SENSOR

The mass flow sensor is an application of an anemometer. The function of this device is
based on King’s law of energy loss from a heated wire4. As can be seen in figure 4.1 the
mass flow sensor contains two metallic filaments situated in a tube that is tapered to
encourage laminar flow. One filament wire is for sensing and the other operates as a
reference. The reference filament tracks the temperature of the airflow passing by it.
The sensing filament is maintained at a preset temperature approximately 50˚C above
the temperature of the reference. When a patient breathes into the mass flow sensor the
gas in the exhaled breath cools the sensing filament.
To maintain the sensing filament at the same offset temperature more power is required
to be delivered to it through an electrical circuit. The quantity of current delivered to
maintain the temperature is proportional to flow. This flow signal is then integrated to
obtain volume. The function of the circuit is to continually heat the sensing filament to a
constant temperature above the reference filament and therefore above the gas
temperature. To enable this to happen, the circuit ‘senses’ the filament temperature by
reading the filaments electrical resistance.
The amount of electrical current required to raise the filament temperature back to its
designated temperature is known from the control circuitry. The current flows in one
direction only and is driven on the inside pins (figure 4.2). The second set of pins reads
the voltage drop. The voltage drop occurs when gas molecules remove heat from the
sensing filament. This voltage drop is fed through a series of pins, cables and cable
connectors back to the circuitry where it is read.
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FIGURE 4.2

FIGURE 4.3

4.4

MASS FLOW SENSOR2

MASS FLOW SENSOR CIRCUITRY2

INDICATIONS FOR SPIROMETRY TESTING

Spirometry testing has the advantage of been non-invasive, well standardised, relatively
short in duration with results available immediately post-test, and for these reasons it is
indicated in a variety of clinical situations5 included in Table 4.1. As outlined in chapter
1, spirometry testing is gaining acceptance as an essential tool not only for quantifying
the degree of lung impairment in COPD, but also as a screening tool for the detection of
this disease in individuals at risk, such as smokers 6,7.
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TABLE 4.1
Diagnostic

INDICATIONS FOR SPIROMETRY TESTING
To evaluate signs and symptoms
To measure the effect of disease on lung function
To screen individuals at risk of having pulmonary disease and
assess prognosis
To assess pre-op risk
To determine the degree of reversibility

Monitoring

To assess therapeutic intervention
To describe the course of disease that affects lung function
To monitor those exposed to agents known to be toxic to the
lungs
To monitor for drugs known to have pulmonary toxicity

Disability/Impairment To assess patients as part of a rehabilitation programme
To assess risk as part of an insurance evaluation

Public Health

Epidemiological surveys
Derivation of reference equations and in clinical research.
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4.5

MEASUREMENT TECHNIQUE
Spirometry results depend largely on patient effort and understanding. The

enthusiasm and attention to detail of the individual carrying out the test also plays an
important role in obtaining accurate and reproducible measurements. In order to assure
reproducibility between spirometry tests and also between test centres, guidelines on
spirometry measurement have been published. Table 4.2 provides a summary of these
guidelines8. Maintaining the comfort and safety of the subject during testing is as
important as the technique itself. The first measurement made in a spirometry test, is the
subject’s standing height. Special attention must be given to this measurement as height
together with gender and age are essential in acquiring the correct reference values used
for interpretation of results. Interpretation and reference equations are covered in section
4.9. During a spirometry test, subjects are encouraged to remain seated upright
throughout, as forced manoeuvres can cause prolonged interruption of venous return to
the thorax causing a sudden dizziness referred to as syncope. Clothing around the chest
and neck is loosened to allow for full chest expansion and a nose clip is used to ensure
there are no air leaks during the manoeuvre. Every effort must be made at this
preparation stage to ensure that the patient is comfortable. Patients are asked to sit
straight with both feet on the ground. Tight clothing is loosened and water and tissues
are made available. Spirometry begins with a maximum inhalation followed by a forced
expiration that rapidly empties the lungs. Despite efforts to maintain patient comfort
during a spirometry test the manoeuvre can prove to be a very uncomfortable
experience for patients with airways disease and elderly patients, as the sustained long
expiratory efforts required in the measurement can be tiresome.
The start of expiration must be swift, without any hesitation. The expiratory effort must
continue for as long as possible or until a plateau in exhaled volume is reached
signifying an ‘end of test’ criterion of < 25 ml over one second. There must be no
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slowing down or malingering during the expiration as both have been shown to
underestimate expired volume9. Maximum encouragement is given throughout the test,
as sub-maximal efforts have been found to lead to spuriously high values10. An
incorrectly inserted mouthpiece may lead to a sub-maximum effort therefore it is
important that the patient has inserted the mouthpiece properly to ensure the expiratory
volume is expelled smoothly and without obstruction by the tongue or false teeth. The
patient is encouraged to rest between successive trials, as the technical acceptability of
each manoeuvre is appraised. At least three forced manoeuvres of acceptable technical
quality are required from any spirometry test session. Tables detailing technical
acceptability and test reproducibility from forced expiratory manoeuvres can be found
in appendix B. Table 4.2 outlines the procedure required to produce an accurate
spirometry measurement.
TABLE 4.2

PROCEDURES FOR RECORDING A SPIROMETRY
MEASUREMENT

Instruct and demonstrate the test to the subject, to include
1
correct posture with head slightly elevated
Attach nose clip, place mouthpiece in mouth and close
2
lips around the mouthpiece
Inhale completely and rapidly with a pause of <1 s at a
3
full lung capacity
Exhale maximally until no more air can be expelled while
4
maintaining an upright posture
5

Repeat instructions as necessary, coaching vigorously

6

Repeat for a minimum of three manoeuvres
Check test repeatability and perform more manoeuvres as

7
necessary, no more than eight are usually required
52

4.6

MEASUREMENT VARIABILTY

To provide a spirometry result for interpretation that is an accurate reflection of an
individual’s lung function at the time of testing, involves an understanding not only of
the limitations of the measurement but the factors that combine to make the
measurement variable. A Combination of both technical and biological factors are
responsible for most of the variability associated with spirometry. Technical factors can
be controlled somewhat by following a quality assurance program that involves
attention to calibration and instrument control checks.
Biological variability has been shown to be greater when spirometry measurements are
made weeks and months apart and in subjects with respiratory disease11,12. There are
two types of biological variation, inter-individual (within-individual variation) and
intra-individual (between-individual variation). An understanding of the role that both
sources of variation play is important when it comes to interpreting a spirometry
measurement. The primary source of inter-individual variation was found to be
circadian rhythm, body and neck position and a sub-maximal spirometry effort, after
accounting for short term variations caused by disease, drugs, smoking and instrument
errors. Both host factors such as gender, height and age, and ethnicity and
environmental factors such as the impact of tobacco smoke, general pollution and
socioeconomic background all contribute as sources of intra-individual variation13.
In a large study carried out on quality control in spirometry testing in eight separate
spirometry testing facilities14, findings demonstrated that more variability was
attributable to using different operators than between identical spirometer devices. This
study emphasises that training and a standardised procedure are equally important
factors when it comes to reducing variability and improving the accuracy of a
spirometry test.
4.7

SPIROMETRIC PARAMETERS
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Breathing is a passive unconscious motion in non-diseased lungs. In a cycle of
breathing approximately 500 ml of air are moved in and out of the lungs and this is
called tidal volume (VT). An excursion from this type of resting breathing will produce
a volume, for example a full breath in to maximum capacity from a tidal breathing
position is termed the inspiratory reserve volume. There are three distinct lung volumes
and a combination of two or more volumes will produces a capacity. The measurements
of lung volume and capacity are critical determinants of overall lung function. Figure
4.4 shows the position of each of volume and capacity of the human respiratory system.
A definition of each lung volume and capacity can be found in appendix C.

FIGURE 4.4

LUNG VOLUME AND CAPACITIES3

A single spirometry manoeuvre will produce an array of volume and capacity
measurements. The most common spirometric parameters derived from a forced vital
capacity manoeuvre are described below.
4.7.1 VITAL CAPACITY (VC) AND FORCED VITAL CAPACITY (FVC)

54

Vital Capacity (VC) is the maximum volume of air that can be exhaled (or
inhaled) from a position of full inspiration (or full expiration). When this vital capacity
is measured from a forced manoeuvre it is called a Forced Vital Capacity (FVC). The
FVC can be reduced in both obstructive and restrictive ventilatory disorders. In
obstructive lung disease mucous plugging and constriction of the airways can reduce the
volume of air to be expired. In restrictive lung disease the distensibility of the lung
tissue itself may be compromised resulting in an inability to move a sufficient capacity
of air out of the lung. A reliable FVC can only be achieved when a subject can
forcefully exhale all the air out of his or her lungs up to the point where the airways
close, called residual volume. This is called the end of test point and corresponds to a
position whereby less than 25 ml of air are left to exhale.

4.7.2 FORCED EXPIRATORY VOLUME AT (t) SECONDS (FEVt)
The forced expiratory volume at (t) seconds is the volume of air expired during a given
time interval (t) from the beginning of the forced vital capacity manoeuvre. The FEVt
can be at 0.5, 3 or 6 seconds, but the FEV at 1 second is the most widely used
standardised parameter in lung function15. The FEV1, just like the FVC, can be reduced
in both obstructive and restrictive airway diseases. A distinction between these two
patterns of dysfunction can be inferred by relating the FEVt to the vital capacity and
expressing it as a ratio FEVt/VC.

4.7.3

RATIO OF
(FEV1/FEV6)

EXPIRED

VOLUME

TO

FLOW

(FEV1/FVC)

and

The FEV1/FVC ratio is the standard index for assessing and quantifying airflow
limitation. However, this ratio naturally declines with age in adults due in part to loss of
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elastic recoil of the lungs16. The FEV1/FEV6 ratio is relating how much volume is
expired in the first second of a forced vital capacity manoeuvre to that expired after six
seconds.

4.7.4

FORCED AVERAGE EXPIRATORY FLOW AS A PERCENTAGE OF
FVC (FEF 25-75%)

The forced expiratory flow (FEFx-y) is the average flow rate during a given volume of
the FVC manoeuvre. X-Y refers to the portion of the FVC for which this average flow is
measured. FEF x-y is expressed as a percentage of the FVC. The portion of 25% to 75%
of the capacity expired is called the maximal mid expiratory flow rate or the forced
expiratory flow from 25% to 75% of the exhaled volume. (MMEFR or FEF 25-75%). This
measurement encompasses flow from both the medium sized and the small airways, and
may be a more sensitive indicator for airways obstruction in patients with normal FEV1
and FEV1/FVC values 17.
4.7.5 PEAK EXPIRATORY FLOW (PEF)
A peak expiratory flow (PEF) is a measure of the initial burst of air leaving the lungs
and during testing can be a good indicator of patient effort. It reflects the portion of air
leaving the large airways. Table 4.4 gives a definition of the main parameters measured
during a forced expiratory manoeuvre.
4.7.6 FORCED EXPIRATORY TIME (FET)
The time taken to forcefully exhale a volume of air from a position of full
inhalation to one of full exhalation.
TABLE 4.3 DEFINITIONS OF SPIROMETRIC PARAMETERS
Parameter

Units

Definition

VC

L

The maximal volume of air exhaled from a maximal inspiration
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FVC

L

The maximal volume of air exhaled with maximally forced
effort from a maximal inspiration

FEV1

l/s

The maximal volume of air exhaled in the first second of a
forced expiration from a position of full inspiration

FEV6

L

The maximal volume of air exhaled in the first six seconds of a
forced expiration from a position of full inspiration

FEV1/FVC

%

FEV1 expressed as a percentage of FVC

FEV1/FEV6 %

FEV1 expressed as a percentage of FEV6

FEF25-75%

The mean forced expiratory flow between 25% and 75% of the

l/s

FVC.
PEFR

l/s

The maximum expiratory flow generated during a maximum
forced expiration, starting without hesitation from the point of
maximal lung inflation

As well as producing an array of spirometric measurements, most spirometers also
provide a graphical representation of exhaled volume. The ability to view a graphical
representation of the manoeuvre is essential for assessing patient effort and appraising
test acceptability. The fact that healthy lungs provide very reproducible graphs and
diseased lungs can alter these graphs in a characteristic manner makes visual inspection
of the overall shape of the graphs very significant for interpretation purposes.

4.8 EXPIRATORY FLOW VOLUME CURVES
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The terms graph and curve are used to describe the graphical representation of a forced
expiratory manoeuvre. Most spirometer devices have the facility to produce a graphical
representation of the forced expiratory manoeuvre in the form of a plot of volume
expired over time called a Spirogram, and or, flow rate plotted against volume, called a
flow volume curve. Tracings allow for inspection for maximal patient effort and
manoeuvre acceptability. The availability of a flow volume curve tracing can assist in
test interpretation due to the fact that the flow volume tracing produces a very
characteristic shape in certain lung diseases due the physiological phenomenon of
dynamic airway compression as discussed in chapter 3. Figure 4.5 shows the spirogram
of a subject with healthy airways who expired maximally. Volume is displayed on the x
vertical axis and time on the y horizontal axis.

SPIROGRAM4

FIGURE 4.5

5
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The volume exhaled is started at time zero or at the point of full inspiration, called total
lung capacity (TLC), and as the patient expires forcefully the tracing rises abruptly as
air leaves the large airways and then starts to plateau off as air is squeezed from
progressively smaller airways until a point is met where no more air can be physically
expired, a point known as the residual volume (RV) of the lung. The initial increase
from time zero to where the line begins to curve represents the volume of air leaving the
large to medium airways. The line then starts to ‘shoulder’ as air is forced from the
medium to small airways and then plateaus as the small airways empty, trapping the
essential residual volume that keeps the lungs inflated.
Forced vital capacity can be measured directly from the spirogram tracing by extending
a straight line from the point where the tracing plateaus to the y axis. Where this line
intersects the y axis is the forced vital capacity measured in litres. A measurement of
flow in the first second FEV1 is made by extending a vertical line from 1 second on the
time scale to touch the curve and from this point a horizontal line is extended to the y
axis where volume can be read. The FEF

25-75%

can be calculated by dividing the FVC

volume by two and dividing this by the time required to expire the middle half of the
FVC.

FEF 25-75% = ½ FVC/∆t

Equation 4.1

where ∆t = the time difference between 25% and 75% points on the curve.
The second type of tracing produced is the flow volume curve when flow rate in litres
per second (l/s) is plotted against volume in litres (l) up to the total volume exhaled. The
same spirometric information contained in the spirogram also exists in the flow volume
curve, but this type of tracings makes it easier to see the subtle changes that may occur
in the small airways.
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It is also easier to see technique faults with this type of tracing. Fig 4.6 shows a typical
flow volume curve from a subject with no airways disease. There is a rapid rise to peak
expiratory flow as air is initially forced from the large airways, but the curve then
descends gradually with no interruption back down to zero flow as the lungs empty.

FIGURE 4.6 FLOW VOLUME CURVE5

4.9

INTERPRETATION

In interpreting a spirometry test, consideration is given to the quality of the
measurement with respect to patient effort, test acceptability and test reproducibility and
to the many different sources of variation as discussed in section 4.6. When all of these
factors have been taken into account the work of interpreting whether a given set of
spirometry results are ‘normal’ or ‘abnormal’ begins with a comparison to reference
values based on a population of ‘healthy’ subjects who had performed spirometry
testing under similar conditions. These reference equations are usually pre-programmed
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into the spirometer’s microprocessor and are easily accessible. There are wide choices
of reference equations available, but differences in interpretation using different
reference equations have been documented, highlighting the need to choose a reference
set that is compatible with the population being tested18. Guidelines on lung function
interpretation do not recommend any specific set of equations for use in Europe but do
suggest the need for a new updated set of equations19. Reference equations are an
important element of spirometry testing because without them interpretation would be
very difficult. The following section provides some background information as to how
these reference values are produced.

4.9.1

REFERENCE EQUATIONS
Stature and age play important roles in the establishment of spirometric

reference equations. Stature can be used to empirically scale lung volumes and
ventilatory flows and age has been shown to have a linear relationship with decline in
lung function20. The development of the lung does not take place uniformly with stature,
and differs between genders; females have on average smaller lungs and larger airways
than men of comparable size21. In childhood lung growth reflects the normal body
growth which continues up to the age of puberty. During puberty which occurs at
approximately age 12 years in girls and age 14 years in boys there is a natural growth
spurt after which a plateau occurs in lung function followed by an age-related decline22.
This rate of decline is related not only to body changes but is also influenced somewhat
by environmental factors23. The decline observed in lung function can begin during the
plateau phase after puberty and has shown to occur earlier in smokers than in nonsmokers 24.
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In respiratory medicine, assessment of lung function and grading of severity of lung
disease requires accurate interpretation of the various lung function parameters. This
interpretation process requires knowledge of what constitutes a ‘normal’ lung function
measurement and a ‘normal’ level of decline. Normal in this context is taken to be a
particular circumstance that does not exceed certain limits or does not deviate from an
average or standard established for a group, class or species25. To aid in the
interpretation of measured data, lung function analysis relies on mathematical models
called regression equations from which reference or normal values are calculated.
Interpretation involves relating a measured value to a reference value in order to
determine if the result falls within a predefined range of normality. One such method is
to compare a new measurement with a previously recorded baseline measurement. This
technique is only practical in a situation where serial measurements are recorded
routinely for example in an occupational screening program. More commonly,
measured data are compared with average values from a representative population for
which a reference range has been pre-determined by statistical analysis. A reference
population in the context of lung function is a group of healthy individuals without
relevant disease from which multiple regression equations have been statistically
determined and which take into account the variables that determine the reference
equation. In order to secure an accurate comparison the reference set chosen must be
comparable to the patient population in terms of both biological and analytical
variability.
Measurement of lung function is subject to large variation and age, stature, sex and
ethnicity in reference equations have been shown to only account for some 40-50
percent of this variability26. In an effort to minimise the many sources of variability that
exist in lung function, selection of appropriate reference sets that fit the population
being tested in terms of both biological variability and analytical compatibility is
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required. Both the European and the American Respiratory Societies have published
detailed recommendations on the procedures and techniques of lung function27 which
have been recently been updated. These together with the host values are the factors to
be considered when selecting a reference set.
Studies designed to produce reference equations can be described as cross-sectional or
longitudinal. In a cross-sectional study, each participant is examined once at a single
point or period in time. In a longitudinal study, the participant is examined at predefined periods of time. Most lung function reference equations have come from an
amalgamation of cross sectional studies from many research groups and are subject to
the ‘cohort effect’. The cohort effect describes the changes that may take place in the
characteristics of a population such as a change in nutrition, environmental conditions,
and other such factors which may have evolved from when data were first collected.
When data have been collected from a reference population they are subjected to
statistical analysis in order to generate a reference value and reference range for a
specific spirometry or lung function parameter. For each parameter measured in the
reference population, an average value is calculated and a measure of the variability
around the average is given. Average and variability are statistical terms that can be
described using a ‘normal’ or Gaussian distribution. In a normal distribution, the
average measure is called the mean and the measure of the variability is called the
standard deviation (SD).

4.9.2 DEFINING NORMALITY
Pulmonary function variables can be described in terms of a Gaussian distribution
where the mean and the standard deviation determine the range of normality. In a
normal distribution the mean is represented by the 50% line, half of the observations are
below the predicted and half above the predicted. Figure 4.7 shows a Gaussian
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distribution which applies the empirical rule stating that 68% of the observations fall
within ±1 standard deviation of the mean, 95% of the observations fall within ± 2
standard deviations of the mean and 99.7% of the observations fall within ± 3 standard
deviations of the mean. Each standard deviation represents the probability that a single
measured value will fall within a certain distance from the mean.

FIGURE 4.7

GAUSSIAN DISTRIBUTION6

A method of determining how far a result is from its predicted value is to express it in
terms of the number of standard deviations the result is from the predicted. This is
called the residual standard deviation (RSD).
In figure 4.7, one SD from the predicted value represents 68% and two SD represents
96%. In numerical terms one SD either side of the predicted line is -1.64.RSD or +1.64
RSD. The addition or subtraction of 1.64.RSD from the mean predicted value results in
an upper or lower limit of normality

28

. The addition of 1.64.RSD from the predicted

value will give the upper limit of normal (ULN) the subtraction of 1.64 RSD from the
predicted value will give the lower limit of normal (LLN). In 95% of individuals RSD is
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less than 1.64 times the RSD and this is called the 95th percentile. In 5% of individuals
the RSD is less than -1.64.RSD, this is called the 5th percentile.
The area between -1.64.RSD and +1.64.RSD in a Gaussian distribution comprises 90%
of the population. 1.64. RSD is also referred to as the limit of normality. By defining the
LLN as 1.64.RSD below the predicted line we are accepting a false positive rate of 5%.
A spirometry result that deviates from the expected value by greater than 1.64 times the
RSD is taken to indicate that the spirometry measurement is abnormal, and this will be
true in 95% of cases but may be an outlier in 5% of cases in individuals with healthy
lungs.

4.9.3 DEFINING AIRFLOW OBSTRUCTION USING LOWER LIMITS OF
NORMAL (LLN)
Current recommendations on the standardisation of lung function endorse the
use of limits of normality to accurately interpret lung function29. When defining airflow
obstruction the use of lower limits of normal (LLN) can be used. All reference
equations have pre-defined upper and lower limits of normal. In spirometry testing if a
parameter is below its pre-defined lower limit of normal it is said to be an ‘abnormal’
finding.
In terms of airways obstruction, as mentioned in section 4.7.3, the FEV1/FVC ratio is
the standard index for assessing and quantifying airflow limitation. However current
practice is to have what is called a fixed limit or a direct comparison of a measured
value against its reference value to obtain a percentage predicted. An example of the use
of fixed limits is the definition of an FEV1 of 80% predicted or an airflow ratio
FEV1/FVC >70% which are often used to define normality30. Fixed limits however have
been found to be scientifically unfounded especially when applied to extremes of age
and height and so tend to increase the likelihood of interpretative errors31. Because the
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FEV1/FVC ratio decreases physiologically with age, the use of fixed limits may result in
many false positive diagnoses in older subjects. The joint ATS/ERS guidelines on
interpretation published in 2005 define an obstructive ventilatory abnormality as a
reduced FEV1/VC ratio below the 5th percentile of the predicted value. They also
acknowledge that early obstructive changes can be seen in the FEF 25-75% parameter but
that this parameter is not specific for small airways disease in individual subjects.32

4.10

SUMMARY

This chapter introduced the technical elements involved in spirometry testing and
underlined the importance of achieving a spirometry manoeuvre that is both technically
acceptable and reproducible. A section on reference equations and lower limits of
normal serve to introduce the method in which spirometry values were used to detect
the presence of airways obstruction in this thesis.
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CHAPTER 5.

5.1

LITERATURE REVIEW

INTRODUCTION

This chapter sets out to provide a brief chronology and commentary of previous studies
pertaining to the use of the forced expiratory volume at six seconds (FEV6) as a
surrogate for the forced expiratory volume (FVC) in lung function testing. The
measurement of a forced vital capacity (FVC) coupled with the expression of this
capacity as a function of time, the forced expiratory volume in one second (FEV1) and
their ratio FEV1/FVC, are the cornerstone parameters for spirometry measurement and
interpretation. Definition of these FVC parameters by Tiffenau and Pinelli1 in the late
1940s has firmly endured in spirometric testing despite six decades of medical research
and technological advances.
The undeniable importance of the spirometric ratio FEV1/FVC as a capable independent
predictor of morbidity due to chronic obstructive pulmonary disease (COPD) and also
mortality due to cardiovascular disease and lung cancer coupled with the increase of
lung disease worldwide has led to growing support of spirometry as a major player in
early diagnosis of lung diseases in particular COPD 2.

5.2

BACKGROUND

The accuracy and reproducibility of a spirometry measurement is dependant on
equipment functioning properly, on the physiologist’s training and motivation, and on
the subject’s test performance3. In an effort to reduce variability and hence improve
accuracy, guidelines on spirometry testing were first published in the early 1980s by
Thoracic Societies on both sides of the Atlantic. More recently joint guidelines issued
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by the European Respiratory Society and the American Thoracic Society have provided
a standardized approach to spirometry testing and interpretation4.
To obtain a spirometry measurement that is technically acceptable certain criteria must
be adhered to. One such criterion refers to when a forced expiratory effort has reached
its natural end. Technically this criterion is satisfied when a subject’s expired breath
shows no volume change (<25ml) in ≥1 second. In practical terms the end of test
criterion has proven to be the most difficult and demanding for patients. In the clinical
setting it is not unusual to have patients with prolonged expiratory times that extend
beyond 10 seconds. This inevitably results in significant strain and discomfort for the
patient as they are frequently encouraged to continue expiring until the end of test
criterion is satisfied. In response to the need for an alternative end of test criterion,
interest in a forced expiratory manoeuvre of a duration that could be easily attained by
the majority of adults was investigated.

5.3

STUDIES INTO AN ALTERNATIVE END OF TEST POINT (FEV6)

The catalyst for research into an FVC manoeuvre of fixed duration came in the form of
FEV6 as proposed by Glindmeyer et al.5 in 1987. In an effort to ascertain test
reproducibility in a large sample of patients undergoing spirometry testing it was found
that an expiration time of 6.64 seconds was more than adequate to discern an acceptable
and reproducible test result. Although this finding demonstrated that a truncated FVC
manoeuvre of six second duration, FEV6, reflected sufficient time to obtain test
reproducibility, interpretation of spirometry results using this new parameter awaited
the publication of up-to-date reference equations and lower limits of normal for a wide
range of spirometry indices to include FEV6 and its ratio FEV1/FEV6.
This finding seemed very promising as it offered the possibility of a shorter forced
expiratory manoeuvre that fitted the criteria for an acceptable and reproducible test. In
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theory this shortened manoeuvre would be less distressing for patients who have long
expiratory times, i.e. those with obstructive airways disease and elderly patients.
In the United States a study called the National Health and Nutrition Examination
Survey (NHANES) published its third set of findings6 in 1994. This survey was
designed to obtain nationally representative information on the health and nutrition
status of a US population through interview and physical examinations. Participants of
this survey underwent spirometry testing to assess their lung function status. Utilizing
spirometric data collected by this survey from life-long non-smokers aged 8-80 years
with no history of lung disease, a group of researchers, Hankinson et al.7, created and
published spirometric reference equations and lower limits of normal for FVC and
included for the first time equations for the shorter spirometry manoeuvre FEV6.
Both the NHANES III and another similar large American multi-centre survey, the
Lung Health Survey (LHS)8, conducted at the same time, drew similar conclusions from
their data. Both groups acknowledged spirometry as being effective in identifying mild
airways obstruction in their participants who smoked, many of whom had previously
denied any chest symptoms on interview. A statement documenting the importance of
spirometry in detecting airways obstruction in asymptomatic adults was made. In
response a subgroup known as the National Lung Health Education Program (NLHEP)9
was established to evaluate the role of spirometry testing as a means of assessing lung
disease. This re-evaluation of the role of spirometry in light of previous research led the
NLHEP group to conclude that, coupled with the appropriate reference equations,
Glindmeyer’s proposal of FEV6 as a possible surrogate to FVC to detect early lung
disease warranted further research. The need to advocate spirometry as a screening test
in the primary care setting was the rationale behind their support for this shorter FVC
manoeuvre. A handheld spirometer with electronic quality control statements guiding
the operator in obtaining accurate results, coupled with a shorter test manoeuvre would
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make spirometry a more attractive tool in screening. Following from this a number of
studies were conducted with the common aim of investigating the credibility of FEV6 as
an alternative to FVC in detecting abnormal spirometry.
For FEV6 and FEV1/FEV6 to have any diagnostic status, a statistical evaluation of the
ability of this new parameter to differentiate normal from abnormal spirometry resultsas defined by the statistical terms sensitivity, specificity, and positive predictive value
(PPV) and negative predictive value (NPV) needed to be assessed. A section detailing
the statistical methods used in this research and in other papers cited in this chapter is
dealt with in chapter 6.
Swanney et al.10 were the first researchers to analyse and publish findings on the new
FEV6 parameter. This group retrospectively analysed spirometry data from 502 patients
attending a New Zealand hospital. They found the new FEV1/FEV6 ratio to be a good
substitute for the traditional FEV1/FVC ratio in its ability to detect abnormal lung
function. As part of this analysis, Swanney et al. directly compared FEV6 to FVC and in
doing so found FEV6 to be less variable and more reproducible.
The ability of the FEV6 parameter to accurately diagnose abnormal spirometry will
depend on the prevalence of this abnormality in the population being tested. In
Swanney’s research population approximately two thirds of the subjects had
documented airways obstruction i.e. the prevalence of obstruction was 65.6% leading to
the high positive predictive value (PPV) of 98.6% experienced by that research group.
This meant that a patient with airways obstruction had been correctly diagnosed with
airways obstruction using FEV1/FEV6, 98.6% of the time.
Results from that study looked promising for FEV6, but as the authors pointed out in
their discussion, more work was required by other researchers using larger numbers of
subjects in a population with a different prevalence of obstruction, to confirm their
findings.
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This call was answered by Vandervoode et al.11 who analysed spirometry data from a
much larger patient group (11,676) with an overall prevalence of obstruction of 39.9%.
Results in terms of both sensitivity and specificity for FEV6 were very similar to the
previous researchers. A lower prevalence of obstruction in this group of subjects
produced a lower PPV (89.8% vs. 98.6%), whereas the negative predictive value
(NPV), in which a subject with normal lung function was correctly diagnosed as normal
spirometry, using the new ratio was higher (96.0% vs. 91.1%). Vandevoorde and coworkers’ research added more weight to the argument that FEV6 could be substituted
for FVC without affecting the test’s ability to detect abnormal spirometry.
Following this, in a study of 5,114 Turkish patients who underwent spirometry as part
of their lung function assessment, Demir et al12 found FEV6 to underestimate FVC and
so produce relatively low sensitivity (86%). They found this to be particularly evident in
cases where the forced vital capacity measurement was more than 1 litre greater than the
forced expiratory volume after six seconds. The reduced sensitivity experienced by this
research group was not surprising given the ‘fixed cut off ‘method employed to classify
airways obstruction. In the study a spirometry result producing an FEV1/FVC or an
FEV1/FEV6 ratio below a fixed 70% was deemed abnormal. In using the same fixed cut
off point for both ratios, this group failed to consider that both ratios not only decline
with age but also with forced expiratory time13. To properly compare FEV1/FVC with
FEV1/FEV6 in the context of defining airways obstruction using a fixed cut-off point, an
FEV1/FEV6 which best predicted an FEV1/FVC ratio of 0.70 would need to be
calculated using appropriate statistics.
This was duly researched in another study by Vandervoode et al. on the role of FEV6
with the purpose of determining fixed cut off points for FEV1/FEV6 and FEV6 in the
detection of abnormal spirometry14. As traditional criteria for detecting abnormal
spirometry involves the use of fixed cut off points15 this study unlike that of Demir et al.
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sought to provide fixed cut of points specifically for the FEV6 parameter. Results from
this study showed that FEV1/FEV6 <73% can be used as a valid alternative to
FEV1/FVC <70% in the detection of airways obstruction. The authors rightly caution
the use of fixed cut off points in spirometry interpretation, as this practice has been
found to be statistically unsound particularly in the elderly age group due the fact that
they fail to take into account the natural age related decline in the FEV1/FVC and
FEV1/FEV6 parameter, leading to the potential for misclassification16. However, as this
group also pointed out there are no specific European spirometric reference equations
and lower limits of normal for FEV1/FVC and FEV1/FEV6 covering all age ranges. Until
such reference equations are established the practice of using fixed cut off points will
remain widespread.
The next major study on FEV6 to be published reviewed its role in detecting abnormal
spirometry in the workplace setting. Alkpinae et al.17 hypothesized that the FEV6
parameter would, in this setting, result in a ‘low misclassification’ rate for detecting
airways obstruction, compared to the traditional FVC parameter. Spirometry results for
1,143 workers from four workplace settings were analyzed using appropriate reference
equations and lower limits of normal for both parameters.
The authors concluded that FEV6 could be used as a reliable substitute for FVC in
detecting abnormal spirometry in the workplace setting. Results showed that only 3.8%
of workers in this study were classified differently by the two techniques thus yielding a
high sensitivity and low misclassification rate. This research was a departure from
previous studies looking specifically at the diagnostic ability of FEV6 in the clinical
setting. In the workplace setting there is perhaps a greater reliance on good quality
spirometric results for accurate interpretation from a medico-legal standpoint as the
potential for developing lung disease from workplace exposures may exist in certain
circumstances.
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In a study published by Hansen et al.18 the use of FEV6 in detecting airways obstruction
was critically analyzed. Spirometry data from the NHANES III survey was used in this
retrospective study. By substituting FVC with FEV6 the authors found that the
sensitivity of a spirometry test to screen for obstruction was reduced, particularly in
elderly subjects and subjects with mild airways obstruction as defined by the FEV1/FVC
ratio. This prompted the authors to call into question the utility of FEV6 in producing an
accurate diagnosis in these two specific groups.
In response to the recommendation from the NHLEP advocating spirometry as a
screening test in primary care settings, Gleeson et al.19 published a study on the
accuracy of the FEV6 in detecting abnormal spirometry at a community hospital. This
study assessed the concordance of FEV1/FVC and FEV1/FEV6 using NHANES
reference equations and their own routinely used reference equations. Better sensitivity
for detecting abnormal spirometry was found in their study group using the NHANES
equations but moderate specificity was found when using their own reference equations.
This study cautioned the use of FEV6-based interpretation of spirometry results in a
primary care setting irrespective of the reference equations chosen, citing the
importance of motivated trained professionals in administering spirometry in an effort
to curtail poor quality results.
The agreement between FEV1/FEV6 and FEV1/FVC in an elderly population was
further investigated by Melby et al.20. This group analysed spirometric data from a large
sample of Norwegian subjects over 60 years of age. They reported the mean difference
in both ratios, regardless of gender to be 2.7%. On further analysis they found this
difference to be more pronounced in smokers and those with a reduced FEV1/FVC ratio.
In response to previous research on fixed cut -off points this group sought to create
fixed cut -off points specifically for their elderly study group. A fixed cut-off point of
73% for FEV1/FEV6 was found to be the best substitute for an FEV1/FVC cut-off point
78

of 70%. This mirrored the results obtained for fixed cut-off points by the Vandervoode
et al. group. The authors concluded that the FEV1/FEV6 ratio was a good substitute for
FEV1/FVC in an elderly population.
Reference equations are paramount in allowing investigators to determine the
diagnostic accuracy of the shortened FEV6 manoeuvre. However currently the only
reference equations available for a wide age range (8-80) years that include the shorter
FEV6 parameter are those published by Hankinson from NHANES III data. The choice
of reference equations in spirometry testing has been shown to have a significant effect
on the interpretation21. In a recent consensus22 from experts on both sides of the Atlantic
in an effort to standardize interpretation of lung function, choosing reference equations
that accurately match the population being studied was advocated, while at the same
time acknowledging the lack of widespread spirometric reference equations that take
into account the rate of decline of lung function with age. In response to this dearth of
appropriate spirometric equations for elderly subjects, studies have been published in
recent years giving more equations and lower limits of normal for subjects over 60
years 23, 24.
In particular Garcia-Rio25 published reference equation for European males and females
in the age range 65-85 years and included for the first time reference equations and
lower limits of normal for the FEV6 and FEV1/FEV6 for European elderly adults. The
availability of these equations provided the means for investigating the agreement
between FEV6 and FVC in diagnosing airways obstruction in patients over the age of 65
years in this thesis. The most recent addition to the library of FEV6 reference equations
has been published by a group of New Zealand researchers26 for a New Zealand
population of European origin aged 25-75 years.
Updated European spirometric reference equations for a widespread age range to
include reference equations and lower limits of normal for FEV6 parameters will lead
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the way to much needed research into the utility of the FEV6 parameter in spirometric
detection of abnormality and in particular into early screening at a primary care level.

5.4

SUMMARY

The majority of research publications to date show that FEV6 is a suitable alternative to
the traditional FVC manoeuvre. Although the methods used to compare FEV6 to FVC in
the research studies outlined in this chapter are similar to this research, this study is the
first to our knowledge to compare FEV1/FEV6 and FEV1/FVC using the Garcia-Rio
reference equations for elderly subjects aged 65-85 years.
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CHAPTER 6

6.1

METHODOLOGY

INTRODUCTION

This chapter gives a brief summary of the methodology used for each of the three main
sections of this thesis. Ethics approval for this research study was sought and granted by
the ethics committee of the Bon Secours Hospital Group and specific request to include
the spirometry data from patients under the care of three referring consultant respiratory
physicians was sought and granted. Spirometry was performed using the same mass
flow- sensing spirometer (Sensor Medics Vmax 22 +Autobox V6200, Viaysis
Healthcare), and the author of this thesis was responsible for carrying out each
spirometry test included in this study. Equipment specification sheets are included in
appendix D. The highest pre-bronchodilator FVC, FEV1 and FEV6 were included in the
analysis.
All numeric values are given as mean ± standard deviation. All of the data contained in
this study were obtained retrospectively. Non parametric t- tests were chosen as the
most suitable tests for evaluating the data in study 1. Statistical significance was taken
at p < 0.05 level, and a statistically highly significant was taken as p < 0.001. Symbols
are used to denote degrees of significance of the results tables in chapter 7. The system
used is *, **, and *** to mean P<0.05, 0.01 and 0.001 respectively 1. 2-by-2
contingency tables2 are the statistical method chosen as the most suitable way to display
data in sections B and C for statistical evaluation.
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6.2

(SECTION A) THE SPIROMETRIC FINDINGS
COMPARED TO NON-SMOKERS

OF SMOKERS

As our objective in this study was to investigate the usefulness of spirometric
parameters and in particular the new FEV6 parameters in providing an early indicator of
dynamic airway changes in smokers we carried out a retrospective search of the
pulmonary function database to included patients with an FEV1 and an FEV1/FVC of
greater than 75% of predicted. This search produced n = 156 smokers (91 female,65
male) and n = 178 non-smokers (111 female, 67 male). Smokers in this study were
patients who smoked at the time of testing either daily or occasionally. Non-smokers
were patients who had not smoked at all at the time of testing3. We chose the following
demographic variables and spirometric parameters to compare both groups.

Demographics variables:
Age (Years)
Height (cm)
Weight (kg)
Body Mass Index (kg/m2)
Gender
Spirometric parameters
FVC
FEV6
FEV1/FVC
FEV1/FEV6
FEF25-75%
FET
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The spirometric parameters obtained represent the highest pre-bronchodilator from tests
containing at least three spirometry manoeuvres. Each spirometry manoeuvre was
assessed according to recently published guidelines on standardisation of spirometry
testing4 and passed as acceptable and reproducible.
Data are presented as mean percent predicted ± standard deviation and statistical
significance was determined using non-parametric two tailed t-tests (Table 7.1).
Data from the smoking group were sorted by the number of cigarettes smoked daily
Two groups were established, Group 1 consisted of smokers with a self-reported
consumption rate of less than 20 cigarettes per day (n = 67) and Group 2 greater than 20
cigarettes per day (n = 89). Data are presented as mean percent predicted ± standard
deviation and statistical significance was determined using non-parametric two tailed ttests (Table 7.2)
Data were sorted by gender to compare male smokers (n = 65) to male non-smokers
(n = 67) and female smokers (n = 91) to female non-smokers (n = 111). Results are
presented as mean percent predicted ± standard deviation and statistical significance
was determined using non-parametric two tailed t-tests (Tables 7.3 and 7.4)
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6.3

(SECTION B) A COMPARISON OF FEV1/FEV6 WITH FEV1/FVC IN
DIAGNOSING AIRWAYS OBSTRUCTION

A retrospective search of the pulmonary function database over a period of 4 months
resulted in n = 171 patients, female (n = 87), male (n = 84). Only patients with
spirometry data meeting the acceptability and reproducibility criteria set out in table 6.1
were included in this study.
TABLE 6.1

INCLUSION CRITERIA

Abrupt start of test with a back extrapolated
volume < 150 ml of FVC
No evidence of cough
No evidence of glottis closure
A Forced Expiratory Time (FET) of at least
6 seconds duration
Three spirometry trials with each FEV1 and
FVC within 150 ml of each other
Evidence of a satisfactory end of test (EOT)
criterion (< 25 ml expired over 1 second)

Applying the above criteria resulted in 72 patients (33 female, 39 male) being excluded
from the study. Subject demographics, specific reasons for exclusion and spirometry
results of the excluded group are given in appendix E.
Of the remaining 99 subjects (55 female, 44 male) we calculated a mean and standard
deviation on the following highest pre-bronchodilator measured spirometric parameters
FVC, FEV6, FEV1, FEV1/FVC, FEV1/FEV6, FEF25-75%, FET and the following subject
variables, age, height, gender and body mass index. (Chapter 7, Tables 7.5 and 7.6).
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An inter-subject coefficient of variation (CoV) was calculated for FEV1/FVC and
FEV1/FEV6, by dividing the mean standard deviation of the ratio by the mean of the
ratio and multiplying by 100 to obtain the percentage CoV.

STUDY B1
The data were then sorted by age into four categories.
Category 1

20-29 years (n = 4)

Category 2

30-49 years (n = 24)

Category 3

50-69 years (n = 49)

Category 4

70-89 years (n = 22).

The mean measured FEV1/FVC and mean measured FEV1/FEV6 were compared for
each category. (Table 7.7)

STUDY B2
Data were then sorted by the degree of airways patency as defined by the mean
measured FEV1/FVC ratio, into four groups.
Group 1

FEV1/FVC > 80

2

FEV1/FVC 70-80

3

FEV1/FVC 50-69

4

FEV1/FVC < 50

The mean measured FEV1/FVC and mean measured FEV1/FEV6 were compared for
each category. (Table 7.8).
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STUDY B3
In order to assess the diagnostic ability of FEV1/FEV6 in identifying airways obstruction
we compared the measured FEV1/FVC and FEV1/FEV6 to their corresponding lower
limit of normal values. Lower limit of normal equations were obtained from the
NHANES III reference set 2 are given in appendix F. If the measured value of the ratio
was higher than its corresponding LLN value, the test was categorised as not obstructed.
If the measured value was less than its LLN, the test was categorised as obstructed. To
determine the sensitivity and specificity of the FEV1/FEV6 ratio in diagnosing airways
obstruction a 2*2 contingency table was constructed. A sample contingency table is
shown in table 6.2. The terms positive and negative are used to refer to the presence or
absence of airways obstruction.

TABLE 6.2

SAMPLE CONTINGENCY TABLE
TP

FP

FN

TN

TP = True positive (FEV1/FVC < LLN and FEV1/FEV6 < LLN)
TN = True negative (FEV1/FVC > LLN and FEV1/FEV6 > LLN)
FP= False positive (FEV1/FVC > LLN and FEV1/FEV6 < LLN)
FN =False negative (FEV1/FVC < LLN and FEV1/FEV6 > LLN)

Sensitivity, Specificity, positive predictive value (PPV) and negative predictive value
(NPV) were calculated following the Bland and Altman definitions 5
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Sensitivity = TP/ (TP+FN)

Equation 6.1

Specificity = TN/ (FP+TN)

Equation 6.2

PPV = Sensitivity * prevalence
Sensitivity*(1-Specificity)*(1-prevalence)

Equation 6.3

NPV= Specificity* (1- prevalence)
(1-sensitivity)*prevalence+ specificity*(1-prevalence)

Equation 6.4

Values that fall into the FP and FN categories are referred to as discordant cases. The
subject demographics and mean measured FEV1/FVC and FEV1/FEV6 ratios of
discordant cases together with their LLN values were calculated (Table 7.9).
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6.4

(SECTION C) FEV1/FEV6 AS A SUBSTITUTE FOR FEV1/FVC IN A
SUBGROUP OF ELDERLY PATIENTS USING TWO SETS OF
REFERENCE EQUATIONS

A retrospective search of the pulmonary function database was conducted for subjects
aged 65-85 years who could exhale for at least six seconds and who met the clinical
guideline criteria for this, resulted in n = 68 patients (35 female,33 male). Over the
course of this research project our pulmonary function database was upgraded6 to allow
us to input a specific search pattern to include only those subjects meeting the inclusion
criteria set out in (Table 6.1)
Mean and standard deviation values were obtained for age, height and FET (table 7.11)
and FVC, FEV6, FEV1, FEV1/FVC, FEV1/FEV6, and FET (Table 7.12)
We compared FEV1/FVC and FEV1/FEV6 to the lower limits of normal from the
NHANES III spirometry reference set7, and constructed a contingency table as
described in section 6.3. This was repeated using reference equations and lower limits
of normal from the Garcia-Rio spirometry reference set8 (Table 7.13 and 7.14),
appendix G.

6.5

SUMMARY

This chapter provided a brief description of the methodology used for the three results
sections included in chapter 7.
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7

RESULTS AND DISCUSSION

7.1

INTRODUCTION

This chapter consists of results and discussion relating to the three main experiments to
achieve the aims set out in Chapter 1.We have subdivided our results into three sections,
Sections A, B and C. Section B is subdivided further into B1, B2 and B3. The heading
of each section is as follows.

Section A:
The spirometric findings of smokers compared to non-smokers.
Section B:
1. The effects of age on FEV1/FVC and FEV1/FEV6
2. The effects of the degree of airway patency on FEV1/FVC and FEV1/FEV6
3. Comparison of the FEV1/FEV6 ratio to the FEV1/FVC ratio in its ability to
accurately diagnosis airways obstruction.
Section C:
Comparison of two different sets of FEV6 reference equations and the ability of each set
to detect airways obstruction in a group of elderly patients

Each section begins with a brief summary of the aim of the study, a table(s) of results, a
discussion of results, and a brief summary. The methodology and statistical method
used for each study is outlined in Chapter 6.
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SECTION A
7.2

THE SPIROMETRIC FINDINGS OF SMOKERS COMPARED TO NONSMOKERS

7.2.1 AIM OF STUDY
The aim of this study is to investigate whether a significant difference exists in the
spirometric parameters of smokers compared to non-smokers. Among the parameters
are the FEV6 and the FEV1/FEV6 ratio. Smoking has been found to be a strong
independent risk factor for the development of chronic obstructive pulmonary disease
(COPD), and a high proportion of COPD patients are smokers1. Cigarette smoking in
particular has been documented in numerous cross-sectional and longitudinal studies to
be an important determinant of the level of lung function reduction.2,3,4. However, other
factors increase the likelihood of developing COPD and include passive exposure to
tobacco smoke5, air pollution6, history of childhood respiratory infections7, presence of
airway hyper-responsiveness8, alpha-1 antitrypsin deficiency9, and occupational
inhalation hazards10. Spirometry testing has the ability to identify mild airflow
abnormalities in asymptomatic smokers. In particular, a reduction in the FEV1/FVC
ratio has been shown to be a strong predictor for rapid progression of COPD11 in
subjects with a ‘normal’ FEV112. All subjects in this study had an FEV1/FVC and an
FEV1 of greater than 75% predicted.
In this study we hypothesised that by including data from patients with ‘normal’
spirometry, subtle differences in lung function between smokers and non-smokers may
be detected. In particular we chose to investigate if the FEV6 parameter could provide
any additional information regarding early airway changes in subjects ‘at risk’ of
developing COPD, our smoking group. We also looked at the possibility of a gender
difference in susceptibility to smoking. The values presented in tables 7.1, 7.2, 7.3 and
7.4 are mean percent-predicted ( standard deviation) for smokers and non-smokers.
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7.2.2 RESULTS
In this study the results presented in table 7.1 show the mean age of the non-smoking
group to be 54.4 years (SD 16.3) and BMI 27.2 (SD 5.1),with the mean age of the
smoking group 53.6 (13.7) years and mean BMI 26.9 (5.1). The mean percent predicted
FVC of non-smokers is 92% (SD 12.1) and in smokers, this was found to be 94% (SD
10.6). The mean FEV6 of the non smoking group is 93% (SD 12.3), and in the smoking
group is 94% (SD 10.3). The FEV1/FEV6 ratio of non-smokers yielded the same mean
% predicted as the FEV1/FVC, 99%. However, the FEV1/FEV6 standard deviation
value was slightly lower 6.08 compared to a SD of 7.4 for the FEV1/FVC ratio. In
smokers both FEV1/FVC and FEV1/FEV6 had a mean percent predicted of 96% but
again the FEV1/FEV6 ratio produced a lower SD of 6.0 compared to a SD of 7.6 for
FEV1/FVC in this group. The mean forced expiratory time of smokers was 9.4 (2.5)
seconds and non-smokers 8.5 (2.2) seconds.
TABLE 7.1 DEMOGRAPHICS AND SPIROMETRY DATA OF NONSMOKERS AND SMOKERS
Parameter

Non- Smokers n= 178
(111 female)

Smokers n=156
(91 female)

P value

FVC

92.312.1

93.910.6

0.218

FEV6

93.112.3

93.910.3

0.545

FEV1/FVC

99.87.4

96.27.6

0.0001***

FEV1/FEV6

99.16.1

96.36.0

0.0001***

FET
(seconds)
FEF25-75%

8.52.2

9.42.5

0.0007***

93.228.2

82.526.2

0.0004***

AGE (years)

54.416.3

53.613.7

0.648

BMI (kg m2)

27.2  5.1

26.9  5.1

0.590

Values presented above are mean % predicted  SD
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In Table 7.2 our results show that among our total smoking group 67 patients smoked
on average less than twenty cigarettes a day, and 89 patients admitted smoking greater
than 20 cigarettes a day. All mean percent predicted spirometric values are lower in the
> 20 per day group compared to the < 20 per day group, but the statistical difference
was not significant.
Smokers who consumed > 20 cigarettes per day were on average 4 years older 55(13.3)
years compared to an average age of 51(14.2) years for patients with a < 20 per day
habit.

TABLE 7.2 SMOKERS WITH <20 AND > 20 CIGARETTES SMOKED/DAY
Smokers
> 20/day
(n = 89)
93.110.0

p value

FVC

Smokers
< 20/day
(n = 67)
95.011.1

FEV6

95.010.5

93.110.0

0.266

FEV1/FVC

96.78.0

95.97.3

0.532

FEV1/FEV6

97.06.1

96.16.0

0.590

FEV1

92.012.2

89.610.6

0.193

FEF 25-75%

85.427.4

80.424.9

0.244

FET

9.42.6

9.42.4

0.884

AGE

51.614.1

55.213.3

0.109

BMI

26.54.8

27.25.7

0.386
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0.287

In Table 7.3 our results show a similar number of male smokers (n = 67) and male nonsmokers (n = 65). Male smokers were on average slightly older, 51(12.8) years, than
male non-smokers, 48(17.0) years, and had longer forced expiratory times 9.75(2.5)
seconds compared to 8.48(2.3) seconds. Both FEV1/FVC and FEV1/FEV6 ratios were
significantly lower in male smokers than in male non-smokers. The mean FEF25-75% in
male smokers was 85% (26) compared to 93% (26) for male non-smokers.

TABLE 7.3 MALE SMOKERS AND NON-SMOKERS
Parameter

Male non-smokers n = 67
(mean  SD)

Male smokers n = 65
(mean  SD)

p value

FVC

92.312.8

92.99.3

0.756

93.59.2

0.907

FEV6
93.312.5
FEV1/FVC

100.06.9

96.77.8

0.0115*

FEV1/FEV6

99.05.5

96.36.3

0.0083**

FEF25-75%

93.526.1

85.026.0

0.05

FET

8.52.3

9.82.6

0.010**

AGE

48.317.0

50.912.8

0.326
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In Table 7.4 results on female smokers (n = 91) and female non-smokers (n = 111)
show that female smokers have mean percent predicted FEV1/FVC, FEV1/FEV6, FET
and FEF25-75% that are lower than female non-smokers, by a statistically significant
difference, represented by a p value < 0.05.

TABLE 7.4 FEMALE SMOKERS AND NON-SMOKERS
Parameter

Female non-smokers n= 111
(mean  SD)

Female smokers n = 91
(mean  SD)

p value

FVC

92.212.3

94.611.3

0.161

FEV6

92.912.2

94.211.0

0.465

FEV1/FVC

99.67.7

95.97.5

0.0007***

FEV1/FEV6

99.06.4

96.35.9

0.0024**

FEF25-75%

92.929.4

80.826.0

0.003**

FET

8.52.1

9.32.40

0.012*

AGE

58.214.4

55.614.1

0.205

BMI

27.6 5.4

26.5 5.6

0.157
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7.2.3 DISCUSSION
Subjects tested were all patients referred to the pulmonary function laboratory for
various clinical reasons. A proportion of this study group had suspected pulmonary
disease and cannot be strictly classed as a ‘normal’ population. However the selection
process ensured that only ‘normal’ spirometry data were included for both groups.
Details on selection process and analysis are given in Chapter 6.
When statistical analysis was applied to the data, in the form of the non-parametric
student’s t-test, subject age and body mass index (BMI) were found to be comparable
between both groups. We found no statistically significant difference between smokers
and non-smokers in FVC and FEV6 values. The average FEV6 parameter expressed as a
percent of predicted for both groups showed a very close agreement with its
corresponding FVC, but did not offer any additional information regarding possible
early signs of change in lung function in the current smoking group. Regardless of
smoking history the FEV1/FEV6 ratio did exhibit a lower standard deviation (SD) value
indicating that this parameter is a less variable, more definite end of test point compared
to the FEV1/FVC ratio.
In a group of middle aged men and women, mean age 54(15) years having performed
spirometry testing for various clinical reasons we found a significantly lower
FEV1/FVC, FEV1/FEV6, FEF25-75% and FET in smokers compared to non-smokers.Both
ratios FEV1/FVC and FEV1/FEV6 were reduced in the smoking group compared to the
non-smoking group. From a clinical viewpoint, both smokers and non-smokers in our
study have ratios that would be considered well ‘within normal limits’13, (Table 7.1).
However for the same mean age (smokers 53 years, non-smokers 54 years) the smoking
group may be beginning to exhibit an earlier decline in lung function compared to nonsmokers as shown by the FEV1/FVC, FEV1/FEV6 ratios.
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We can also see from this study that the FEV1/FEV6 ratio declines in a similar manner
to the FEV1/FVC ratio regardless of smoking habit. This finding would suggest that
given similar readings the shorter FEV6 manoeuvre could be used successfully as a
surrogate for the FVC manoeuvre.
The lower SD scores of the FEV1/FEV6 ratio also suggest that this shorter manoeuvre
has less variability. Reducing the variability of this type of measurement may lead to a
more accurate interpretation of the measurement and result in a lower misclassification
rate when it comes to classifying spirometry results as normal or abnormal.
In this study, further evidence of an earlier decline in lung function in smokers with a
normal FEV1/FVC and FEV1/FEV6 ratio can be seen in the reduced FEF25-75%. The
majority of studies into the effects of smoking on lung function have focused on
FEV114,15,16. However, effects may also be revealed in other measures of lung function
such as the FEF25-75%. This parameter is a measure of the average flow rate between 25%
and 75% of the forced vital capacity, and flow rates from this portion of the FVC
specifically reflect the patency of airways < 2 mm in diameter, called the peripheral
small airways. The significance of a reduced FEF25-75% has been investigated in other
studies and although this parameter has a wide variability (reflected in this study by a
large SD value), it has been suggested to be an early indicator of small airways disease
in subjects who have otherwise normal lung function as assessed by means of FEV1 and
FEV1/FVC17. Early studies into small airways dysfunction revealed that COPD affects
the small peripheral airways in its sub-clinical early phase18.
The FEF25-75% parameter is significantly reduced in our smoking group, despite this
group having ‘normal’ ratios. As airflow limitation prolongs the forced expiratory time
(FET), the longer FET in the smoking group may reflect early closing of the peripheral
airways and possibly the significantly reduced FEF25-75%.
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Despite the subtle early differences seen in this study, a longitudinal study of these
patients is warranted to properly assess if the smokers have a greater risk of a rapid
decline in lung function heralding early COPD.
Previous longitudinal studies documented that the FEV1/FVC ratio is a strong predictor
for rapid progression of COPD in smokers19 and recently a study by Enright et al
showed that the FEV1/FEV6 ratio could also predict lung function decline in adult
smokers 20.
Other studies into early detection of COPD through spirometry testing have included
data on the effects of smoking consumption in the form of pack-years. In our study we
did not have access to pack years data, but were able to record the average number of
cigarettes each smoker admitted to smoking per day. These data are included in Table
7.2 and our results show no statistically significant difference in either demographic or
spirometric parameters in the smoking group, as between those smoking on average
greater than 20 cigarettes per day and those smoking less than 20 cigarettes per day.
Other studies in this area have found evidence that the number of cigarettes smoked has
a linear effect on pulmonary function level and rate of loss. In particular a crosssectional analysis in the Six Cities Study21, 23 showed that in comparison to ex-smokers,
current smokers had lower levels of lung function as measured by spirometry. The
subjects included in our study were a mixture of male and female current smokers and
never smokers. To investigate if gender played a role in the differences between
smokers and non-smokers with regard to spirometry values we compared male smokers
to male non smokers and female smokers to female non smokers using student’s t-tests
for statistical significance, the results of which are shown in tables 7.3 and 7.4.
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As shown in tables 7.3 and 7.4 the same parameters, FEV1/FVC, FEV1/FEV6, FEF25-75%
and FET that showed a statistically significant difference in our total smokers compared
to non-smokers group (table 7.1) also showed a statistically significant difference in our
comparison of male smokers to non-smokers and female smokers to non-smokers.
This finding suggests that gender did not give any additional information regarding
subtle differences in smokers and non-smokers in our limited study group. However the
male non-smokers were younger than the male smokers whereas the female nonsmokers were older than the female smokers and this finding may be evidence for the
claim that women are taking up smoking at a younger age. In a study of Irish teenagers,
researchers found that 20.7% of young teenagers actively smoke and significantly more
females than males do so22.
Several longitudinal studies have been published on gender differences in the
susceptibility to cigarette smoking, but there is little clarity, as some studies show the
reduced level of lung function associated with cigarette smoking to be greater in men
than in women23, 24 and other studies report that women are more susceptible 25, 26.

7.2.4 SUMMARY
The initial aim of this study was to investigate if parameters from the shorter six-second
spirometry test could provide early signs of airways obstruction heralding the beginning
of COPD in a group of patients at risk for developing this disease due to their smoking
habits. Our results showed that the FEV6 parameters did not provide any additional
information to that already obtained from the traditional FVC parameters, however the
FEV1/FEV6 ratio did decline in the same manner as the FEV1/FVC ratio in smokers
compared to non-smokers of similar age and demographics. We also found that the
FEV6 parameters and in particular FEV1/FEV6 ratio had a lower standard deviation than
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the FEV1/FVC ratio, suggesting that this parameter may be a more accurate and
reproducible measurement.
Given this finding the shorter FEV6 manoeuvre could be an attractive shortcut to the
traditional FVC spirometry manoeuvre. A shorter manoeuvre would reduce the burden
of the test for those patients with prolonged forced expiratory times and in elderly
subjects.

7.2.5

HYPOSTASIS

To further investigate if the shorter FEV6 manoeuvre could be an alternative to the
traditional FVC manoeuvre, we compared the FEV1/FEV6 ratio to the FEV1/FVC ratio
in their ability to diagnose airways obstruction using reference equations with lower
limits of normal. The results of this study are set out in section B.
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SECTION B
7.3 A COMPARISON OF FEV1/FEV6 WITH FEV1/FVC IN DIAGNOSING
AIRWAYS OBSTRUCTION

7.3.1 AIM OF STUDY
The initial aim of this study was to compare the FEV1/FEV6 ratio to the traditional ‘gold
standard’ FEV1/FVC ratio to determine its ability to detect airways obstruction. We
compared each ratio with its corresponding lower limit of normal value which was
taken from a reference set that included equations for both the traditional FVC and the
‘new’ FEV6 parameters. Detailed equations and lower limits of normal used in this
study can be found in appendix F. Using the spirometric data obtained from patients
included in this study we were able to investigate the behaviour of both FEV1/FVC and
FEV1/FEV6 with increasing age and decreasing airways patency. These two studies are
presented in sections B1 and B2 respectively.

7.3.2 RESULTS FROM SPIROMETRY DATA
In order to assess the ability of the FEV1/FEV6 ratio in diagnosing airways obstruction
we examined spirometry data from a sample of our patient population. The subject
demographics for ninety-nine subjects included in this study are presented in table 7.5.
Mean (SD) age was 56.3(14.6) years and the mean (SD) forced expiratory time (FET)
for the group was 9.4(2.8) seconds. Of the total number of patients included in this
study forty-four were male and fifty-five female. The mean (SD) Body Mass Index
(BMI) was 26.6(5.5) and mean (SD) height was 167(9.8) cm. We also looked at
smoking habits of the group and found that 45 were non-smokers, 46 were ex-smokers,
and 8 were current smokers. Of the current smokers seven out eight were female.
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TABLE 7.5 SUBJECT DEMOGRAPHICS
Subject Demographics

Mean ± SD

Age (years)

56.3 ± 14.6

Age range

42 -70

Height (cm)

167 ±9.8

BMI (kg/m2)

26.6 ± 5.5

TABLE 7.6 SPIROMETRY DATA

Spirometry Parameter

Mean ± SD

FVC %predicted

82.2 ± 16.5

FEV6 %predicted

81.7 ± 18.5

FEV1 %predicted

76.9 ± 22.5

FEV1/FVC %

91.8 ± 15.7

FEV1/FVC measured

71.4 ± 12.6

FEV1/FEV6 %

92.5 ± 11.7

FEV1/FEV6 measured

74.5 ± 9.8

FEF25-75% predicted

71.3 ± 39.8

FET
Mean difference in FEV1/FVC and
FEV1/FEV6 ratios expressed as
measured values
Inter-subject CoV

9.4 ± 2.8
3.1

FEV1/FVC %

17.2%

FEV1/FEV6 %

12.7%
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Spirometry data
In table 7.6, a mean and standard deviation (SD) was calculated for each of the
parameters. The standard deviation represents a measure of dispersion or variability in
the data set. The higher the SD figure the greater the spread of values is around the
mean value. The degree of variation about the measurement for the group is called the
inter-subject coefficient of variation (CoV). In this study the mean inter-subject CoV for
FEV1/FVC was 17.2% and for FEV1/FEV6 was 12.7%.

7.3.3

DISCUSSION

This reduced variability in the FEV1/FEV6 ratio is likely attributed to the FEV6 end-of
test-point. An explicitly defined end-of-test of six seconds duration tends to increase the
accuracy of the expired volume measurement. Therefore, with the FEV6 manoeuvre
terminating the expired volume at exactly six seconds duration variability surrounding
the end of test volume is reduced. Guidelines on spirometry interpretation27,28
recommend that only reference equations that are technically and biologically
appropriate for the population being studied are to be used, as any difference occurring
between the methods in which the reference value and the actual measured value were
obtained can lead to errors in interpretation. Therefore given that the shorter FEV6
manoeuvre has the potential to produce more accurate spirometry results as seen in the
reduced CoV (table 7.6), interpretation of spirometry results from this type of
manoeuvre should only be carried out with the appropriate FEV6 reference equations.
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STUDY B1
7.4 THE EFFECTS OF AGE ON THE FEV1/FEV6 AND FEV1/FVC RATIOS

7.4.1

AIM OF STUDY

In Table 7.5 the patients included in our main study of the comparison of FEV1/FEV6 to
FEV1/FVC in diagnosing airways obstruction had an age range from 42 to 70 years and
we therefore choose to look at the effects that age has on the FEV1/FVC and
FEV1/FEV6 ratios.
7.4.2 RESULTS
The mean measured FEV1/FEV6 and FEV1/FVC values by age categories are given in
table 7.7

TABLE 7.7 MEAN FEV1/FVC AND FEV1/FEV6 BY AGE CATEGORIES
FET
Age years
(± SD)

N

20-29 (± 3.7)

FEV1/FVC
(± SD)

FEV1/FEV6
(± SD)

4

78.2
(± 11.1)

30-49 (± 5.7)

24

50-69 (± 5.0)

70-89 (± 3.8)

p- value
∆ (ml)

(± SD)

78.5
(± 11.4)

0.25

7.0
(±0.5)

0.979

76.5
(± 9.0)

78.2
( ±7.4)

1.6

8.7
(±2.8)

0.500

49

71.1
(± 11.5)

75.0
(± 8.4)

3.9

10.0
(±2.8)

0.184

22

64.4
(± 14.8)

68.4
(± 11.5)

3.9

9.8
(±3.0)

0.341

∆ = absolute difference between both ratios expressed in ml
Values for FEV1/FVC and FEV1/FEV6 reported are mean measured values.
Values for FET are mean average values reported in seconds.
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Both ratios show a decline with increasing age and increasing forced expiratory time
(FET). The mean difference between the FEV1/FVC and FEV1/FEV6 ratios was found
to increase with age from a difference of only 0.25 ml in the younger age bracket 20-29
years to a mean difference of 3.9 ml in subjects aged > 50years. We found no
statistically significant difference between both ratios, p<0.05.
When the data are expressed in graphical form, it is easier to see the decline in both
ratios with increasing age.The mean FEV1/FVC and FEV1/FEV6 ratios are plotted for
each age category in Figure 7.1.

FEV1/FEV6 measured

FEV1/FVC neasured and

Mean FEV1/FVC and FEV1/FEV6 measured by age
category
100
80
FEV1/FVC

60

FEV1/FEV6

40
20
0
19-29

30-49

50-69

70-89

Age category

FIGURE 7.1 MEAN MEASURED FEV1/FVC AND MEAN MEASURED FEV1/FEV6 IS
PLOTTED FOR EACH AGE CATEGORY

7.4.3 DISCUSSION
Maximum lung function is reached at approximately 20 years of age in females and 25
years of age in males29. This is due to the fact that girls reach puberty and attain their
maximum lung size earlier than boys of similar age. In males after puberty, although
growth in stature may cease, growth in lung capacity continues for some years due to
the continued growth of the thorax29. Lung function has been shown in numerous cross
sectional and longitudinal studies to decline naturally with age30,31, and therefore the
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decline in both ratios seen in this study with increasing age is not unexpected. The
normal annual decline in healthy never-smoking adults 35-65 years old has been
determined to be on average 30 ml/year 32. In elderly subjects this age related decline is
accelerated33,34 and can be seen very readily in studies which are conducted for the
purpose of creating reference equations. Such studies incorporate large numbers of
healthy individuals of both sexes and represent a wide spectrum of ages.
A recent study establishing predicted reference values for elderly subjects35
reported that the annual decline in FEV1 values for healthy elderly females was 32
ml/year and for healthy elderly males of 44 ml/year. The same study also predicted the
FEV1/FVC ratio to decline with increasing age from a value of 80% to 70% predicted in
females and from 79% to 73% predicted in males to the lower limits of normal from
71% to 68% and from 70% to 64% respectively. In another large reference based study
conducted in the United States called the National Health and Nutrition Survey III36,
analysis of some 74,294 healthy subjects revealed a slower decline with age with
FEV1/FEV6 than with FEV1/FVC.
Our results mirror these findings showing a less steep decline in FEV1/FEV6 at all ages
compared to FEV1/FVC, (Figure 7.1). Our results also show that the FEV1/FVC ratio
declines with the duration of expiratory effort as indicated in the forced expiratory time
(FET). This finding reflects how the FVC measurement depends on the time taken to
empty the lungs forcefully. Longer expiratory times were needed to obtain the FVC
measurement in subjects over fifty years of age. The age related decline in lung function
can be accounted for by factors associated with ageing such as loss of elastic recoil of
the lung that occurs naturally with age. Studies of the effects of ageing on the human
lung have found that with healthy individuals the elastic recoil pressure decreases as age
increases37,38. Ageing also brings about changes in the respiratory system and each
change plays a part in the natural decline of the lung function parameters FEV1 and FVC
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and hence the ratio FEV1/FVC. These changes include the chest wall becoming stiffer
with age.This stiffness is termed reduced compliance, and may be linked to calcification
in the rib bones and the general geometric changes that occur to the rib cage and thorax
with increasing age.
Structural changes also affect the force generating capacity of the diaphragm, the
main muscle used in respiration and coupled with deficient nutritional status that comes
with age,serve to reduce overall respiratory muscle strength and hence the ability to
generate expiratory force. The principal cause of age-related decline in lung function is
attributed to the nature of the tissues that make up the lung and airways called elastic
and collagen fibers in the lung parenchyma. It is the inherent elasticity of the lungs that
allows expansion on inspiration and enables them to spring back into shape on
expiration. The force used here is called the elastic recoil pressure, and ageing causes
this recoil to diminish, brought on by degeneration or changes in the arrangement of the
elastic fibers.
During forced expiration in elderly subjects the chest wall is stiffer and the lungs are
less elastic allowing inspired air to become trapped within the lungs. This causes the
residual volume (RV) of the lung to increase and in doing so compromises the overall
vital capacity and increases the functional residual capacity (FRC). When air is forced
from the lungs of an elderly subject the natural degeneration of the fibers that support
the walls of the airway cause the small airway (< 2mm) collapse or close more
prematurely than they would in younger lungs. This closure or airway narrowing
prolongs the expiratory time (FET) required to reach the FVC and in turn increases the
variability of the FVC measurement. This is reflected in the results shown in table 7.6,
the FVC parameters with larger standard deviations than the FEV6 parameters, and the
variability in the measurement as reflected by the larger SD increases with increasing
age.
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7.4.4

SUMMARY

This study showed that both FEV1/FVC and FEV1/FEV6 decrease with age, and the
difference between ratios is more pronounced the older the individual. The results of
this study also demonstrate the longer the forced expiratory time the greater the
difference between ratios. We looked at the effects of airway patency on both ratios in
section B2.
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STUDY B2
7.5

7.5.1

THE EFFECTS OF THE DEGREE OF AIRWAY PATENCY ON THE
FEV1/FEV6 AND FEV1/FVC RATIOS
AIM OF STUDY

The FEV1/FVC ratio is widely used in clinical practice to determine if an obstructive
ventilatory effect is present and is a measure of the degree of airway narrowing that
occurs during a forced expiratory manoeuvre39. Using the spirometric data from patients
included in our main study of the comparison of FEV1/FEV6 to FEV1/FVC in the
spirometric diagnosis of airways obstruction, we investigated the difference between
both ratios as the patency of the airway decreases.

7.5.2 RESULTS
In table 7.8 the absolute difference between the FEV1/FVC and FEV1/FEV6 ratio and
the corresponding forced expiratory time in four distinct categories based on the degree
of airway patency as defined by FEV1/FVC are shown.
The mean difference between the measured FEV1/FVC and FEV1/FEV6 becomes
greater the more narrow the airways become, as reflected by a decreasing FEV1/FVC
ratio from a difference of only 0.6 in subjects with an FEV1/FVC of greater than 80 to a
difference of 11.2 in subjects with an average FEV1/FVC of less than 50. There is also a
concomitant increase in the forced expiratory time from 7.2 (0.96) seconds to 15.2
(0.93) seconds. When these data are expressed in graphical form the decline in both
ratios with decreasing airway patency is very apparent. The mean FEV1/FVC and
FEV1/FEV6 ratios are plotted for each value of FEV1/FVC in Figure 7.2
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TABLE 7.8 FEV1/FVC, FEV1/FEV6 AND MEAN FET BY DEGREE OF
AIRWAY PATENCY AS DEFINED BY THE FEV1/FVC RATIO

Airway
patency
>80
(n =24)

FEV1/FVC FEV1/FEV6
(± SD)
(± SD)
83.8 (±2.9) 84.4 (±2.6)

70-80
(n = 44)

75.5 (±2.9)

50-69
(n = 23)

63 (±5.0)

< 50
(n =8)

39 (±4.5)

FET
Difference (± SD)
0.6
7.2 (±1.0)

p-value

0.4450
77.6 (±2.7)

2.1

8.7 (±2.0)
0.0005***

67 (±3.6)

4.0

10.6(±2.6)
0.0005***

50.2 (±3.2)

11.2

15.2(1±.0.9)
0.0001***

FEV1/FVC and FEV1/FEV6 above are represented as mean measured values.
Values for FET are mean average values reported in seconds.

FIGURE 7.2 MEASURED FEV1/FVC AND FEV1/FEV6 BYTHE DEREE OF AIRWAY
PATENCY AS DEFINED BY THE FEV1/FVC RATIO
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7.5.3 DISCUSSION
The FEV1/FVC represents the proportion of air that can be exhaled from the lungs in the
first second of a forced expiratory manoeuvre in relation to the maximum volume of air
that can be expelled from the lungs. The amount expired in the first second is a constant
fraction of that which can be maximally exhaled. The difference between FEV1/FVC
and FEV1/FEV6 becomes more pronounced the more reduced the FEV1/FVC becomes,
from a difference of 0.6 in the group with an FEV1/FVC ratio of > 80, to a difference of
11.2 in the group with an FEV1/FVC ratio of <50, there is also a concomitant increase
in the time taken to empty the lungs forcefully (FET), 7.2 seconds to 15.2 seconds
respectively.
These results clearly show that the more reduced the patency of the airways the longer
the FET becomes and this can be attributable to a number of factors. With a reduced
airway patency known as airflow obstruction the diameter of the airways affected is
narrowed due to excess mucous production and inflammation of the surrounding airway
wall. This narrowing may also be due to a reduced elastic recoil pressure as discussed
earlier which can cause the small airways to narrow early in the forced expiration,
leading to a longer forced expiratory time. The significant difference observed in our
limited study between ratios in the case of decreasing airway patency has the potential
of causing misclassification when it comes to interpreting spirometry results.
In some subjects with airways obstruction the time taken to reach the ‘end-of-test
criterion’ is prolonged well beyond six seconds and the more pronounced the difference
between the FEV6 end of test and the FVC end-of-test point will be.
Figure 7.3 shows a sample volume time curve to illustrate the difference between a
FVC manoeuvre and a FEV6 manoeuvre.

115

FIGURE 7.3 SPIROGRAM DEPICTING THE DIFFERENCE BETWEEN THE TWO END OF
TEST POINTS FVC AND FEV6

In this example the time taken to forcefully exhale a vital capacity breath is
approximately 14 seconds, giving an FVC in this example of 4.9 litres. If the curve is
truncated at six seconds (vertical line at 6 seconds) as would be the case in the shorter
six second manoeuvre, the resulting forced expiratory volume at six seconds (FEV6 ) is
4.6 litres. The forced expiratory volume after one second of exhalation (FEV1) is 3.3
litres and this is the same regardless of the type of manoeuvre used. The FEV1/FVC
ratio is calculated to be 67 but the FEV1/FEV6 ratio due to the smaller denominator is
greater at 72, therefore the shorter FEV6 manoeuvre could underestimate the degree of
airway patency and so create a false negative interpretation. However the potential for
misclassification should be minimised if the correct reference values that have been
derived from the same type of manoeuvre are used.
Interpretation of spirometry employs reference equations that are appropriate both to the
measurement and to the population being studied. Clinical practice guidelines for
spirometry interpretation endorse the use of the appropriate reference equations and
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lower limits of normal to accurately define airflow obstruction40. If the appropriate
reference equations with well described lower limits of normal are used the difference
between a manoeuvre lasting six seconds and the longer FVC manoeuvre will be
accounted for. This was investigated by Demir et al41, who found in a study of 5,114
subjects that among those with an FEV1/FVC ratio of less than 70, only 86% also had
an FEV1/FEV6 less than 70, and that the mean difference between FEV1/FVC and
FEV1/FEV6 expressed as percentages increased from approximately 4 to 9 when
FEV1/FVC decreases from 70% to 50%. They found that if this difference is taken into
account using appropriate reference equations for FEV1/FEV6, then the FEV1/FEV6
ratio from the shorter FEV6 manoeuvre is as good a predictor of airways obstruction as
the traditional longer FEV1/FVC.

7.5.4 SUMMARY
We found in this study that a reduced airway patency causes a prolonged average FET.
The longer the FET the greater the difference between the ratios FEV1/FVC and
FEV1/FEV6. However as other studies have pointed out, using the correct reference
equations and lower limits of normal, FEV1/FEV6 may be used as a surrogate for
FEV1/FVC despite having a fixed shorter FET. This was investigated in our study
population and the results are presented in Section C of this chapter.
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SECTION B3

7.6

FEV1/FEV6 COMPARED TO FEV1/FVC IN THE SPIROMETRIC
DETECTION OF AIRWAYS OBSTRUCTION

7.6.1 AIM OF STUDY
The importance of a diagnostic test is its ability to give the correct diagnosis. It is
unlikely that any diagnostic test is ever accurate all of the time. The diagnostic test of
the FEV1/FEV6 ratio, to be useful must be sensitive enough to determine the correct
diagnosis of airways obstruction in the substantial majority of cases. In this study the
diagnostic ability of FEV1/FEV6 in identifying airways obstruction was tested by
comparison with the ‘gold standard’ FEV1/FVC ratio. Patients were classified into two
distinct groups according to the presence or absence of airways obstruction as defined
by a FEV1/FVC and a FEV1/FEV6 above or below their respective lower limit of normal
values. Results are presented in table 7.9.

7.6.2 RESULTS
Twenty six out of the ninety nine subjects included in this study had a diagnosis of
airways obstruction confirmed by both FEV1/FVC and FEV1/FEV6 and seventy one
subjects had a diagnosis of no airways obstruction confirmed by both ratios. There were
two cases where the diagnosis of airways obstruction differed between ratios, these
were called discordant cases. One subject was diagnosed as having airways obstruction
by the FEV1/FVC ratio alone and the other was diagnosed as having airways obstruction
by the FEV1/FEV6 ratio alone. Sensitivity for the group was calculated to be 96%,
specificity 98%, positive predictive value 95% and a negative predictive value of 98%.
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TABLE 7.9 DIAGNOSIS OF AIRWAYS OBSTRUCTION USING PRECISE
LOWER LIMITS OF NORMAL FOR FEV1/FVC AND FEV1/FEV6
FEV1/FVC

Obstruction

No Obstruction

Total

FEV1/FEV6
Obstruction

26

1

27

FEV1/ FEV6
No Obstruction

1

71

72

Total

27

72

99

Sensitivity: 96.3%, Specificity: 98.6%, Positive predictive value (PPV): 95.6%
Negative predictive value (NPV): 98.8%

7.6.3 DISCUSSION
The proportion of patients with airways obstruction who were correctly diagnosed by
the FEV1/FEV6 ratio (sensitivity) is 96.3% and those with no airways obstruction who
were correctly identified by the FEV1/FEV6 ratio (specificity) is 98.6%. Therefore, in
these patients we would expect 96.3% of patients with airways obstruction to be
correctly identified by the FEV1/FEV6 ratio while 98.6% would be correctly identified
as not having airways obstruction by the same ratio. If a patient is confirmed as having
airways obstruction by the gold standard FEV1/FVC ratio there is a 96.3% probability
that the same patient would also be confirmed as having airways obstruction using the
FEV6 manoeuvre. In this study the use of the FEV6 manoeuvre in predicting
abnormality was also calculated and given as positive predictive value (PPV) and
negative predictive value (NPV) in table 7.4. A PPV of 95.6% represents the proportion
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of patients with airways obstruction for which the FEV6 manoeuvre correctly identified
them as having airways obstruction. A NPV of 98.8% shows the proportion of patients
without airways obstruction which the FEV6 manoeuvre correctly identified. The
calculation of these predictive values is highly dependant on the prior probability of
disease in the population being studied. This is known as disease prevalence. The
prevalence of obstruction in this study population was calculated to be 24/99 (24%).
This meant that before applying the above diagnostic accuracy test; there was a prior
probability (24% chance) that a given patient would have airways obstruction.
These results confirm that replacement of the FVC ‘gold standard’ manoeuvre with a
shorter FEV6 manoeuvre and the use of proper reference equations in our patient
population would not diminish the diagnostic accuracy of the spirometry test in
identifying airways obstruction. The sensitivity of the FEV6 method of 0.96 means that
if a patient is confirmed as having airways obstruction by the gold standard FVC
method there is a 96% chance that that same patient will also be diagnosed as having
airways obstruction by the FEV6 method. Consequently, this leaves 4% of the subjects
studied who may be classified as not having airways obstruction, despite having the
disorder. The specificity result of 0.98 on the other hand provides the scenario that a
subject may be identified as not having airways obstruction by the FVC method there is
a 2% chance that the same subject may be identified as having airways obstruction by
the FEV6 method. An example of this method in practice is shown in table 7.9 for two
cases reported where the two ratios under investigation produced two differing diagnose
or discordant cases.

DISCORDANT CASES
The spirometry test results for two patients were classified differently by the two ratios;
however both had observed values close to their respective lower limits of normal.
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Subject characteristics and spirometry data are presented in Table 7.10. In the first
discordant case the FEV1/FVC was above its corresponding lower limit of normal and
therefore no airways obstruction was deemed to be present. FEV1/FEV6 was at its lower
of limit of normal value and in clinical practice this subject would be deemed to have
airways obstruction. In the second discordant case the FEV1/FVC ratio classified an
obstructive ventilatory pattern as the measured value was at the lower limit of normal
but the FEV1/FEV6 was above its lower limit of normal and therefore airways
obstruction was deemed to be absent in this subject by this ratio.

TABLE 7.10 DISCORDANT CASES
Subject
1
2

Age
(years)
62
63

FET
(seconds)

Gender

FEV1/FVC
(LLN)

FEV1/FEV6
(LLN)

6.5

Female

69 (64)

69 (69)

12.2

Male

65 (65)

72 (70)

LLN refers to lower limit of normal
Difference refers to the measured value minus the lower limit of
normal.
Age is in years
Forced expiratory time (FET) is in seconds

Both discordant cases have ratios that lie close to their lower limits of normal and
therefore should be interpreted with caution. The day-to-day variation that occurs in
spirometric measurements could shift the results across the lower limit of normal value.
Lung function has been shown to exhibit both diurnal and seasonal variation due to
factors such as cyclical changes in blood cortisol and adrenaline levels, ambient
temperature, airways resistance sleep patterns, posture, meals and hormone production
in females42. Reported significant changes in FVC and FEV1 for normal subjects within
a day are 5%, this variability has been shown to increase to 13% for patients with
chronic obstructive pulmonary disease. The equivalent weekly variation in these two
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spirometry parameters is 11% and 20% respectively43,44. In the context of the results
seen in this study and in particular in the two discordant cases shown in table 7.6,
results that lie close to their lower limit of normal can easily shift across this lower limit
of normal threshold and be subject to a different diagnosis. Joint American Thoracic
and European Respiratory Society guidelines on lung function interpretation
recommend caution when interpreting spirometry results that lie close to the lower limit
of the reference range and recommend clinical history and prior probability of disease
as adjuncts in making a definitive diagnosis in these circumstances.The results of this
study are similar to two other large studies published on this same topic. Compared to
Swanney et al.45 in our study we obtained slightly higher values of sensitivity and
specificity (96%, 98% in our study compared with 95% and 97%). Swanney et al had a
larger population of patients (n = 337) with a prevalence of obstruction of 65.5%.
Similarly we obtained higher values in comparison with the Vandervoode et al study46
which had a patient population of 11,676 and a prevalence of obstruction of 39.5%.

7.6.4 SUMMARY
As discussed in Chapter 6 the reference values used in this study are the only published
references equations to date that include the FEV6 parameter in the age range 880(years). Using the reference equations and lower limits of normal taken from a large
American Health Study NHANES III this study demonstrated that the FEV6 manoeuvre
can be used as a surrogate for the FVC manoeuvre in the identification of airways
obstruction in our patient population. We also found a much reduced inter-subject
coefficient of variation in the FEV6 parameter, suggesting that stopping the test at a predefined time of six seconds can significantly reduce the variability of the measurement
and make it a more reproducible and accurate physiological measurement, while not
losing its diagnostic ability.
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SECTION C
7.7

FEV1/FEV6 AS A SUBSTITUTE FOR FEV1/FVC IN A SUBGROUP OF
ELDERLY PATIENTS USING TWO SETS OF REFERENCE
EQUATIONS

7.7.1 AIM OF STUDY
This study was conducted to determine the reliability of FEV6 and FEV1/FEV6 in
detecting airways obstruction in an elderly patient group aged 65-85 years using
European reference values specific to this age group (García-Río et al.)47 and to evaluate
the sensitivity and reliability in detecting airways obstruction using both the American
(NHANES III)48 and the European (García-Río et al.) reference values in this elderly
population. It is in this group of patients that the shorter FEV6 spirometry test may be of
most benefit. As documented in Study B Section 7.3, the forced expiratory time
generally becomes longer with age and so a shorter test will minimize the burden
involved in reaching the standard end -of -test point.
The European reference equations used in this study are the first and only published
spirometric equations to date extracted from a European population of elderly patients
to include the new FEV6 parameters.

7.7.2

RESULTS

In this study we had a total of n= 68 patients, n=35 female and n=33 male. Mean age of
the group was 72 (5.2) years, mean height 167(9.8) centimeters, with females on
average 14 cm shorter than males (Table 7.11). The mean forced expiratory time for the
group was 9.6 (2.6) seconds. The mean measured spirometry parameters are shown in
table 7.12. Mean measured FEV1/FVC for the group is 68.3 with a SD of 12.2 compared
to FEV1/FEV6 of 72.2 with a smaller SD of 9.8.
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TABLE 7.11 SUBJECT DEMOGRAPHICS
Male n = 33 Female n = 35 Total n = 68
Mean Age (years)

72.2  4.8

Mean Height (cm) 174  6.4
Mean FET (sec)

9.8  2.5

72.5  5.7

72.4 5.2

160  7.4

167 9.8

9.4  2.8

9.6 2.6

TABLE 7.12 SPIROMETRY DATA
Spirometry Parameter

Mean (± SD)

FVC measured

2.6 ± 0.8

FEV6 measured

2.5 ± 0.8

FEV1 measured

1.8 ± 0.7

FEV1/FVC measured

68.3 ± 12.2

FEV1/FEV6 measured

72.0 ± 9.8

FET

9.6 ± 2.6

The comparison of FEV1/FVC and FEV1/FEV6 with reference equations and lower
limits of normal from the NHANES III reference set is expressed in a 2-by-2
contingency table (table 7.13). The ratios matched for diagnosis in all but one case
where FEV1/FEV6 diagnosed airways obstruction and the FEV1/FVC categorized this
subject to have no airways obstruction (table 7.14). The sensitivity of the FEV1/FEV6
ratio for correctly diagnosing airways obstruction in this elderly cohort was calculated
to be 100%, specificity 98%, with a positive predictive value of 95% and a negative
predictive value of 100%.
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TABLE 7.13 CONTINGENCY TABLE USING NORTH AMERICAN
(NHANES III) REFERENCE EQUATIONS

FEV1/FVC
Obstruction
FEV1/FEV6

No Obstruction

Total

21

1

22

0

46

46

21

47

68

Obstruction
FEV1/FEV6
No Obstruction
Total

Sensitivity: 100% Specificity: 98% Positive predictive value (PPV): 95% Negative predictive value
(NPV): 100%

TABLE 7.14 DISCORDANT CASE USING NHANES III REFERENCE
VALUES

Subject

Age
(years)

1

78

FET

Gender

(secs)

6.5

Female

FEV1/FVC

FEV1/FEV6

(LLN)

(LLN)

69 (64)

69 (69)

LLN refers to lower limit of normal
Difference refers to the measured value minus the lower limit of normal.
Age is displayed in years
Forced expiratory time (FET) is displayed in seconds

This calculation was repeated using reference equations and lower limits of normal from
the Garcia-Rio reference set, results are expressed as a 2-by2 table (Table 7.15). Using
these equations the sensitivity of FEV1/FEV6 was calculated to be 96%, with specificity
95% ,and positive predictive value of 92.6%, and a negative predictive value of 97.5%.
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FEV1/FVC and FEV1/FEV6 disagreed in their diagnoses of airways obstruction in three
cases using this reference set (Table7.16).
TABLE 7.15 CONTINGENCY TABLE USING EUROPEAN (GARCIA-RIO)
REFERENCE EQUATIONS
FEV1/FVC
Obstruction
No obstruction
25
2

Total
27

FEV1/FEV6
Obstruction
1
40
41
FEV1/FEV6
No obstruction
26
42
68
Total
Sensitivity:96% Specificity: 95% Positive predictive value (PPV): 92.6
Negative predictive value (NPV): 97.5

TABLE 7.16 DISCORDANT CASES USING GARCIA-RIO REFERENCE
VALUES

Subject

Age
(years)

FET

Gender

(secs)

FEV1/FVC

FEV1/FEV6

(LLN)

(LLN)

1

70

10.1

Female

62 (68)

70 (69)

2

67

7

Male

71 (70)

71 (72)

3

77

12.2

Male

65(67)

72 (69)

LLN refers to lower limit of normal
Difference refers to the measured value minus the lower limit of normal.
Age in years
Forced expiratory time (FET in seconds)
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7.7.3 DISCUSSION
The main aim of this study was to investigate the diagnostic ability of the shorter six
second manoeuvre in a subgroup of

patients

that

have

longer

forced

expiratory times (FET), due to the natural

ageing process of the lung and loss of

elastic recoil49. Elderly patients may benefit most from a shorter spirometry manoeuvre,
as less effort is required to reach the end of test point. From our results in Section 7.1,
we found that the mean difference between the FEV1/FVC and FEV1/FEV6 ratios
increased with increasing age and forced expiratory time but using reference equations
with LLNs that included FEV6 parameters, we calculated the diagnostic ability of the
FEV1/FEV6 to correctly diagnose airways obstruction was 96.3%.
The FEV1/FVC ratio obtained from a spirometry or forced vital capacity manoeuvre is
widely used in clinical practice to determine the presence of an obstructive ventilatory
defect or airways obstruction50,51,52. An obstructive ventilatory defect is defined as a
disproportionate reduction of maximal airflow from the lungs in relation to the maximal
volume that can be displaced from the lung53. As the FEV1/FVC ratio is based on the
maximal volume of air that can be exhaled during a spirometry test the accuracy of this
ratio becomes entirely dependent on patient effort and co-operation. In spirometry
testing the ability to reach an acceptable exhaled volume or end of test point and the
ability to reproduce this volume to within 150 ml as stated in the most recent guidelines
on the standardization of spirometry testing53 can be especially difficult for elderly
patients and patients with severe airways obstruction. These patients often require up to
20 seconds to reach what is accepted as an adequate end-of-test point of a volume
change of <25 ml over 2 seconds.
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An alternative end-of test-point, where the forced expiratory volume is explicitly
confined to 6 seconds duration has been suggested to be a more accurate less variable
measurement and one that may be less demanding to perform.
There are numerous reference equations published for forced spirometry
parameters such as the FVC and the FEV1; in the Republic of Ireland over 90% of
pulmonary function laboratories have adopted the 1993 Update European Respiratory
Society spirometry reference values for adults aged 18-70 years54 for their patient
population. Two published reference equations exist for the FEV6 parameter and its
ratio FEV1/FEV6. The Third National Health and Nutrition Examination Survey
(NHANES III) which was derived from a US population aged 8-80 years and the
reference equations by García-Río et al. derived from a Spanish population with an age
range of 65-85years. Studies to date using the NHANES III US reference values for
FEV6 and FEV1/FEV6 have shown FEV6 to be reliable alternative for detecting airways
obstruction (and restriction) in spirometry testing55,56 and that FEV6 can be used as a
surrogate for FVC in the workplace setting57.
Another study published fixed cut-off-points for FEV6 and FEV1/FEV6 that can
be used as a valid alternative to the FVC and FEV1/FVC ratio in the detection of
airways obstruction58. European reference values and lower limits of normal published
to date that include values for FEV6, FEV1/FEV6 and apply to subjects in the age range
of 65-85 years. However it is in this particular group of patients that a shorter test
manoeuvre may be of greater benefit, as it may prevent the undue fatigue and
discomfort and in some cases syncope that can be associated with the standard
prolonged test manoeuvre. In our study we documented that the average forced
expiratory time for the group as a whole was 9.8 seconds, well above the suggested six
second cut off point. The longer forced expiratory times (FET) in this particular cohort
of patients may be due in part to the natural ageing process of the lung. The loss of
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elastic recoil in ageing lungs can mimic an airways obstructive pattern59. The difficulty
with longer forced expiratory times is that they push the standard criteria for end-of-test
further along the expiratory time curve, making it increasingly difficult for the patient to
reach them. The shorter FEV6 manoeuvre has a definite end-of-test of six seconds
duration and so can reduce the effort required by the patient and by the test operator to
meet a longer FVC end of test point. It can reduce overall testing time and may actually
assist in interpretation by reducing the variability of the volume measurement, making it
statistically more accurate when compared with reference values for the same
measurement. In the present study using contingency tables and lower limits of normal,
tables 7.13 and 7.14, we have shown significant agreement between FEV1/FEV6 and
FEV1/FVC in terms of diagnosing airways obstruction in both sets of reference
equations for our elderly cohort and these findings reflect the values obtained in
previous studies in other countries. However we did not get 100% agreement and where
the ratios differed in diagnosis (discordant cases) the actual measured values for each
ratio is very close to its respective lower limit of normal. This was the first study to date
to look at the new FEV6 parameters in terms of diagnosing airways obstruction in a
strictly elderly group of patients, and the first to compare the differences between the
two main reference equations published to date to include FEV6 equations and lower
limits of normal.
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7.7.4

SUMMARY

The results of this study confirm that FEV6 is a more reproducible parameter by
showing the coefficient of variation for FEV1/FEV6 to be 23% less than that for
FEV1/FVC. This reduced variability suggests that the FEV1/FEV6 may be a more
statistically accurate ratio for detecting airways obstruction.
Recently published joint ERS/ATS guidelines on the standardization of spirometry
define an acceptable duration of exhalation as ≥ 6 seconds or the presence of a plateau
to define end-of-test criteria, making way for this new FEV6 parameter to be recognised
as an acceptable surrogate for FVC provided the correct reference values are used. This
work suggests there is need for updated European reference equations to be made
available to include FEV6 and FEV1/FEV6 for all age groups. This study has shown
reduced variability of FEV1/FEV6 compared to FEV1/FVC and therefore that FEV6 has
a role in spirometry testing, especially for patients unable to reach a satisfactory FVC
endpoint. The agreement of FEV1/FVC and FEV1/FEV6 using both reference sets and
the sensitivity/specificity of FEV1/FEV6 in this cohort support the validity of using
FEV6 in the diagnosis of airway obstruction.

130

7.8

REFERENCES
1. National Heart, Lung and Blood Institute. Morbidity and Mortality: 2004. Chart
book on cardiovascular, lung, and blood diseases. Rockville MD: National
Heart, Lung and Blood Institute: 2004

2. Xu X, Weiss ST, Rijcken B et al. Smoking, changes in smoking habits and rate
of decline in FEV1: new insights into gender differences. Eur Respir J 1994;7:
1056-61

3. Burchfield CM, Marcus EB, Curb JD, et al. Effects of smoking cessation on
longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995;
151: 1778-85

4. Sandvik L, Erickssen G, Thaulow E. Long-term effects of smoking on physical
fitness and lung function: a longitudinal study of 1,393 middle aged Norwegian
men for 7 years. BMJ 1995; 311: 715-18

5. Xu X, Li B. Exposure-response relationship between passive smoking and adult
pulmonary function. Am J Respir Crit Care Med 1995;151:41-46

6. Tashkin DP, Detels R, Simmons M, et al. The UCLA population studies of
COPD X1. Impact of air pollution and smoking on annual change in FEV1. Am
J Respir Crit Care Med 1994; 149: 1209-1217

131

7. Weiss ST, Tager IB, Munoz A, et al. The relationship of respiratory infections
in early childhood to the occurrence of increased levels of bronchial
responsiveness and atopy. Am Rev Respir Dis 1985; 131: 73-578

8. O Connor GT, Sparrow D, Weiss ST. The role of allergy and non-specific
airway hyperreponsveness in the pathogenesis of COPD. Am Rev Respir Dis
1989; 140: 225-252

9. Snider GL. Pulmonary disease in alpha-1-antitrypsin deficiency. Ann Intern
Med 1989; 111: 957-959

10. Becklake MR. Occupational and environmental lung disease. Chronic airways
disease: Its relationship to work in dusty occupations. Chest 1985; 88: 608-617

11. Anthonsien Nr, Connett JE, Kiley JP et al. Effects of smoking intervention on
the use of an inhaled anticholinergic bronchodilator on the rate of decline of
FEV1: the lung health study. JAMA 1994; 272: 1497-1505

12. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung Function and
mortality in the United States: data from the first National Health and Nutrition
Examination Survey NHANES follow-up. Thorax 2003; 58: 388-393

13. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F et al. Interpretative
strategies for lung function tests. Eur Respir J 2005; 26: 948-968

132

14. Peat JK,Woolcock AJ, Cullen K. Decline of lung function and development of
Chronic airflow limitation: a longuditional study of non-smokers and smokers
in Busselton, Western Australia. Thorax 1990;45: 32-37

15. Fletcher C,Peto R, Tinker C,Speizer FE. The natural history of chronic
bronchitis and emphysema: an eight year study of early chronic obstructive lung
disease in working men in London. Oxford, UK. Oxford University Press; 1976

16. Anthonsien NR,Connett JE, Kiley JP, et al. Effects of smoking intervention and
the use of an inhaled anticholernergic bronchodilator on the rate of decline of
FEV1: The Lung Health Study: JAMA 1994; 272: 1497-1505

17. Marcq M, Minette A. Lung function changes in smokers with normal
conventional spirometry. Am Rev Respir Dis 1976; 114:723-38

18. Hogg JG, Macklem PT, Thurlbeck WM. Site and nature of airways obstruction
in Chronic Obstructive Lung Disease. N Engl J Med 1968; 278: 1355-60

19. Anthonsien NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and
the use of an inhaled anticholernergic bronchodilator on the rate of decline of
FEV1: The Lung Health Study: JAMA 1994; 272: 1497-1505
20. Enright RL, Connett JE, Bailey WC. The FEV1/FEV6 predicts lung function
decline in adult smokers. Respir Med 2002; 96(6): 444-449

133

21. Dockery DW, Speizer FE, Ferris BG Jr, Ware JH, Louis TA, Spiro A.
Cumulative and reversible effects of lifetime smoking on simple tests of lung
function in adults. Am Rev Respir Dis 1988; 137: 286-292

22. Manning P, Goodman P, Kinsella T,Lawlor M, Kirby B, Clancy L. Bronchitis
symptoms in young teenagers who actively or passively some cigarettes. Ir Med
J. 2002-Aug;95(7):202-4

23. Camilli AE, Burrows B, Knudson RJ, et al. Longitudinal changes in FEV1 in
adults. Effects of smoking and smoking cessation. Am Rev Respir Dis 1987;
135(4): 794-799

24. Xu X, Dockery DW, Ware JH, Speizer FE, Ferris BG Jr. Effects of cigarette
smoking on rate of loss of lung function in adults: a longitudinal assessment.
Am Rev Respir Dis 1992; 146: 855-859

25. Lange P, Groth S, Nyboe J, et al. Effects of smoking and changes in smoking
habits on the decline of FEV1. Eur Respir J 1989; 2: 811-816

26. Langhammer A, Johnsen R, Gulsvik A, et al. Sex Differences in Lung
vulnerability to tobacco smoking. Eur Respir J 2003; 21: 1017-1023

27. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur
Respir J 2005; 26: 153-161

134

28. Roca J, Burgos F, Sunyer J et al. Reference values for forced spirometry. Eur
Respir J 1998; 11: 1354-1362

29. Hurwitz S, Allen J, Liben A, Becklake, MR. Lung function in young adults:
evidence for the differences in the chronological age at which various functions
start to decline. Thorax 1980; 35: 615-619

30. Falaschetti E, Laiho J, Primatesta P, Purdon S. Prediction equations for normal
and low lung function from the Health Survey for England. Eur Respir J 2004;
23: 456-463

31. Enright et al. Spirometric reference equations for healthy middle-aged women
and men Minnesota

32. Garcia-Rio F, Pino JM, Dorgham A, Alsono A, Villamor J. Spirometric
reference equations for European females and males aged 65-85yrs. Eur Respir
J 2004;24: 397-405

33. Janssens JP, Pache JC, Nicod LP. Physiological changes in respiratory function
associated with ageing. Eur Respir J 1999;13: 197-205
34. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the maximum
expired flow volume curve with growth and ageing. Am Rev Respir Dis 1983;
127: 725-734

135

35. Garcia-Rio F, Pino JM, Dorgham A, Alsono A, Villamor J. Spirometric
reference equations for European females and males aged 65-85yrs. Eur Respir
J 2004;24: 397-405

36. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a
sample of the general U.S population. Am J Respir Crit Care Med 1999; 159:
179-187

37. Kerstjens HAM, Rijcken B, Schouten JP, et al. Decline of FEV1 by age and
smoking status: Facts, figures and fallacies. Thorax 1997; 52: 820-827

38. Turner JM, Mead J, Wohl ME. Elasticity of human lungs in relation to age. J
Appl Physiol 1968; 25: 664-671

39. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F et al. Interpretative
strategies for lung function tests. Eur Respir J 2005; 26: 948-968

40. American Thoracic Society. Lung Function testing. Selection of reference
values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-1218.
41. Demir T, Ikitimir HD, Koc N, Yildirim N. The role of FEV6 in detection of
airways obstruction. Respir Med 2005; 99: 103-106

42. Spengler CM, Shea SA.Endogenous circadian rhythm of pulmonary function in
healthy humans. Am J Respir Crit Care Med 2002; 162:1038-1064

136

43. Burrows B, Lebowitz MD, Camilli AE, Knudson RJ. Longitudinal changes in
Forced expiratory capacity in the first second in adults. Methodological
consideration and findings in healthy non-smokers. Am Rev Respir Dis 1986;
133: 974-980

44. Spencer DA, Marshall T, Weller PH, Williams J. A superior method of
assessing the reproducibility of pulmonary function measurements. Am Rev
Respir Dis 1992; 145: A253

45. Swanney MP, Jenson RL, Crichton DA, Beckert LE, et al. FEV6 is an
acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction
and restriction. Am J Respir Crit Care Med 2000; 162:917-919

46. Vandevoorde J, Verbanck S, Schuermans D, et al. FEV1/FEV6 and FEV6 as an
alternative to FEV1/FVC and FVC in the spirometric detection of airways
obstruction and restriction. Chest 2005; 127:1560-1564
47. García-Río F, Pino JM, Dorgham A, Alonso A, Villamore J.Spirometric
reference equations for European females and males aged 65-85yrs.Eur Respir J
2004; 24:397-405

48. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a
sample of the general US population. Am.J.Respir.Crit.Care.Med 1999;
159:179-187

49. Janssens JP, Pache JC, Nicod LP. Physiological changes in respiratory function
associated with ageing. Eur Respir J 1999;13: 197-205
137

50. Millar MR, Hankinson J, Brusasco V, Burgos R ,Casaburi R,Coates A, Crapo
R,Enright et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338

51. BTS/SIGN Guidelines on Asthma. http://www.brit-thoracic.org.uk/asthmaguideline-download.html

52. NHLBI/WHO workshop 1998. Global initiative for chronic obstructive lung
disease.Global strategy for the diagnosis, management,and prevention of
chronic obstructive pulmonary disease.www.goldcopd.org. September 2005

53. Millar MR, Hankinson J, Brusasco V, Burgos R ,Casaburi R,Coates A, Crapo
R,Enright P et al.Standardisation of spirometry. Eur Respir J 2005; 26: 319-338

54. ARTI Audit of Respiratory Laboratories in the Republic of Ireland 2005

55. Swanney MP, Jensen RL, Crichton DA, Beckert LE, Cardno L, Crapo R. FEV6
is an acceptable surrogate for FVC in the spirometric diagnosis of airway
obstruction and restriction.Am.J.Crit.Care.Med 2000:162:917-919

56. Vandevoorde J, Verbanck S, Scheuermans D,Kartounian J,Vincken W.
FEV1/FEV6 and FEV6 as an alternative for FEV1/FVC and FVC in the
spirometric detection of airway obstruction and restriction. Chest 2005;
127:1560-1564

138

57. Akpinar-Elci M, Fedan KB, Enright PL.FEV6 as a surrogate for FVC in
detecting airways obstruction and restriction in the workplace. Eur Respir J
2006; 27:374-377

58. Vandevoorde J, Verbanck S, Scheuermans D,Kartounian J,Vincken W.
Obstructive and restrictive spirometric patterns: fixed cut-offs for FEV1/FEV6
and FEV6. Eur Respir J 2005; 27: 378-383

59. Babb TG, Rodarte JR. Mechanism of reduced expiratory flow with ageing. J
Appl Physiol 2000; 89:505-511

139

CHAPTER 8

CONCLUSIONS

The utility of a shorter six second manoeuvre in spirometry testing has been assessed in
this thesis with a special emphasis showing that spirometric indices measured at six
seconds are clinically useful in detecting airways obstruction. The clinical utility of the
traditional FVC manoeuvre has already been well established with the FEV1/FVC ratio
now firmly accepted as an indicator of the presence of airflow obstruction. However the
FVC manoeuvre is not without problems. The prolonged forced expiratory times
required to meet acceptable end-of-test criteria can be physically exhausting for subjects
with airways obstruction and for elderly and infirm subjects. Also measurements with
expiratory times that take up to or exceed 15 seconds have the potential to cause an
increase in measurement variability. In addition an increase in the prevalence of
respiratory disease worldwide, particularly COPD, has led to a renewed interest in
making spirometry testing more user-friendly and less variable, thereby facilitating
widespread implementation of spirometry as a means of detecting airways obstruction
in its sub-clinical phase.
An alternative to the traditional FVC manoeuvre is the forced vital capacity at six
seconds (FEV6). In our investigations into the clinical utility of the FEV6 manoeuvre we
investigated if parameters measured at six seconds exhalation could provide any
additional information regarding early detection of airways obstruction in smokers with
otherwise normal spirometry values. The findings of this study revealed that a
significant difference existed in the FEV1/FVC ratio between smokers and non-smokers
and that the FEV1/FEV6 ratio mirrored this finding. While the FEV6 parameters did not
provide us with any additional information regarding early indicators of airways
obstruction, parameters measured at six seconds can be successfully used as a surrogate
for the FVC manoeuvre in this study group. We also found that parameters measured at
140

six seconds are less variable and therefore are more easily interpreted with accuracy.
The findings of this section of the thesis reveal that the FEV6 measurement has a role to
play in spirometry testing but further studies regarding its diagnostic ability are
required. A longitudinal study of the spirometry results of smokers compared to nonsmokers to include parameters measured at six seconds would give further scope to
properly assess the merits of the FEV1/FEV6 ratio in providing additional information
regarding accelerated lung function decline in smokers.
The diagnostic ability of the FEV1/FEV6 ratio to reliably detect airways obstruction
using appropriate reference equations and lower limits of normal compared to the ‘gold
standard’ FEV1/FVC ratio was assessed. The results of this thesis confirm that forced
expiratory volume in six seconds FEV6 can be used as a surrogate for FVC in our adult
patient population. We also confirmed that FEV6 spirometry values are more
reproducible and less variable than FVC values. We also compared FEV6 to FVC in
terms of detecting airways obstruction in an elderly patient group aged 65-85 years
using two different reference sets. One set was from a North American population, and
the second set was the only European spirometry reference set to date to include FEV6
parameters, and specific to the age group being studied, 65-85 years. It is for this
specific age group that a shorter spirometry manoeuvre such as the FEV6 would be of
greater benefit by easing the burden of the test. Given the naturally longer forced
expiratory times that accompany natural ageing of the lung the potential for larger
differences between parameters measured at the traditional FVC manoeuvre and those
measured at six seconds exhalation FEV6 exist. The findings of this study confirm that
the FEV1/FEV6 is as good as FEV1/FVC in detecting airways obstruction in this age
group using both reference sets in our patient population. Where diagnosis differed
between ratios, the actual measurements when inspected lay close to their respective
lower limit of normal values. A spirometry value close to, or at, its lower limit of
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normal value could be due to the day-to-day variation shift across this limit, meaning
the same test may yield a different diagnosis if repeated some days apart. Therefore
spirometry values that lie close to their lower limit of normal value should be
interpreted with caution.

8.1

SUMMARY

This work demonstrates that the shorter FEV6 manoeuvre is as effective as the
traditional FVC manoeuvre in the detection of airways obstruction in our patient
population, provided the appropriate reference equations and lower limits of normal are
used. We found the FEV6 parameter to be more reproducible than the FVC parameter,
with prolonged expiratory times having a smaller impact on FEV6 reproducibility than
on FVC reproducibility.
The physical impact of a shorter FEV6 manoeuvre will be more pronounced in subjects
where multiple prolonged forced expiratory efforts are commonly required to satisfy
reproducibility criteria, for example with elderly subjects and subjects with airways
obstruction. Lowering the forced expiratory time to six seconds will reduce the
likelihood of procedure related syncope (which is light headiness, faintness) general
fatigue and distress that can accompany a session of numerous prolonged forced
expiratory efforts. A fixed expiratory time of six seconds has been shown in this study
to significantly reduce the variability of the test, and therefore improve the overall
accuracy of the test. In addition the agreement of both FEV1/FVC and FEV1/FEV6 in
terms of sensitivity and specificity support the validity of using FEV6 in the spirometric
detection of airways obstruction.
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8.2

Further Work

Using FEV6 based spirometry values to detect airways obstruction could increase the
popularity of spirometry testing in the primary care setting where the number quality of
testing may not be as good as that in a hospital based lung function department. The
shorter test manoeuvre coupled with the reduced variability of this measurement may
provide a means of reducing the risk of mis-classification in this setting. As we have
shown in this work FEV6 parameters are less variable and therefore more reproducible
than the standard FVC parameters. We have also shown that among other spirometric
parameters the FEF25-75% is significantly reduced in smokers compared to non-smokers.
The diagnostic ability of the FEF25-75% has always been limited because of its high
variability; this was demonstrated in our work with inter-subject SD values of up to
29.0, compared to SD values for FEV6 of approx 12.0.
The greater variability in this measurement is partly due to the variability of the FVC
measurement, since this measurement is calculated from 25% and 75% of the end value
FVC. Determining FEF25-75% from a six second manoeuvre, which has proven to be less
variable, may provide a more accurate means of detecting early airway changes
compared to other tests of lung function.
For more work to be carried out on the clinical utility of the FEV6 manoeuvre in
pulmonary function new updated European reference equations and lower limits of
normal for spirometry values to include FEV6 are required over a wide age range, and
especially for subjects over the age of 75 years.
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APPENDIX A

RANGE AND ACCURACY RECOMMENDATIONS FOR SPIROMETERS*

Test

Range/accuracy (BTPS)

Flow
Range
0-14

Time
L.s-1
30

Resistance and
Back pressure

Test Signal

0.5-8 L, ±3% of reading or
3-L Calibration
± 0.050 l, whichever is
syringe
greater
24 ATS waveforms
0.5-8 L, ±3% of reading or
0-14
15
<1.5cmH20.L-1.s-1
FVC
(0.15 kPa.L-1.s-1)
3-L Calibration
± 0.050 l, whichever is
syringe
greater
0.5-8 L, ±3% of reading or
0-14
1
<1.5cmH20.L-1.s-1
FEV1
(0.15 kPa.L-1.s-1)
± 0.050 l, whichever is
greater
The time point from which
Back Extrapolation
Time zero
all FEVt measurements are
taken
26 ATS waveforms
Accuracy: ± 10% of reading
0-14
Mean resistance at
PEF
or ± 0.30L.s-1 (20 L.min-1)
200, 400, 600 L.min-1
whichever is greater;
(3.3, 6.7, 10 L.s-1)
must be <2.5
repeatability: ±5% of reading
cmH20.L-1.s-1 (0.25
or ±0.15 L.s-1
-1
(10 L.min ), whichever is
kPa.L-1.s-1)
greater
Data from
<1.5cmH20.L-1.s-1
Accuracy ± 5% of reading or 0-14
Instantaneous
-1
(0.15 kPa.L-1.s-1)
manufacturers
± 0.200 L.s , whichever is
flows
greater
(except PEF)
7.0 L.s-1, ± 5% of reading or
24 ATS waveforms
± 14
15
Same as FEV1
FEF 25-75%
± 0.200 L.s-1 , whichever is
greater
Sine wave pump
250 L.min-1 at VT of 2 L
± 14
12<1.5cmH20.L-1.s-1
MVV
(0.15 kPa.L-1.s-1)
within ± 10% of reading or ± (±3%) 15
15 L.min-1, whichever is
greater
BTPS: body temperature and ambient pressure saturated with water vapour; VC: vital capacity; FVC: forced vital
capacity; ATS: American Thoracic Society; FEV1: forced expiratory volume in one second; FEVt: forced
expiratory volume in t seconds; PEF: peak expiratory flow; FEF25-75%: mean forced expiratory flow between 25%
and 75% of FVC; MVV: maximum voluntary ventilation; VT: tidal volume.
VC

* Millar MR, Hankinson J, Brusasco V, Burgos R ,Casaburi R,Coates A, Crapo R,Enright P et al.
Standardisation of spirometry. Eur Respir J 2005; 26: 319-338
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APPENDIX B
SUMMARY OF WITHIN-AND-BETWEEN-MANOEUVRE ACCEPTABILITY
CRITERIA*

Table 5 Summary of within-and between-manoeuvre
acceptability criteria
Within-manoeuvre criteria
Individual spirograms are “acceptable” if
They are free from artefacts [3]
Cough during the first second of exhalation
Glottis closure that influences the measurement
Early termination or cut-off
Effort that is not maximal throughout
Leak
Obstructed mouthpiece
They have good starts
Extrapolated volume < 5% of FVC or 0.15L, whichever is greater
They show satisfactory exhalation
Duration of ≥ 6 s (3s for children) or a plateau in the volume-time curve or
If the subject cannot or should not continue to exhale
Between-manoeuvre criteria
After three acceptable spirograms have been obtained, apply the following
tests
The two largest value of FVC must be within 0.150 L of each other
The two largest value of FEV1 must be within 0.150 L of each other
If both of these criteria are met, the test session many be concluded
If both of these criteria are not met, continue testing until
Both of the criteria are met with analysis of additional acceptable spirograms
or
A total of eight tests have been performed (optional) or
The patient/subject cannot or should not continue
Save, as a minimum, the three satisfactory manoeuvres
FVC: forced vital capacity; FEV1: forced vital capacity in one second

* Millar MR, Hankinson J, Brusasco V, Burgos R ,Casaburi R,Coates A, Crapo R,Enright P et al.
Standardisation of spirometry. Eur Respir J 2005; 26: 319-338
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APPENDIX C
DEFINITION OF LUNG VOLUMES AND CAPACITIES*
Volume (units: millilitres)

Definition

Tidal volume (Vt)

Volume of gas inhaled and exhaled during each
respiratory cycle

Inspiratory reserve volume

Maximal volume of gas exhaled from end

(IRV)

inspiration

Expiratory reserve volume

Maximal volume of gas exhaled from end

(ERV)

expiration

Residual volume (RV)

Volume of gas remaining in the lungs after a
maximal expiration
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APPENDIX D

Vmax Series

SPECIFICATIONS

Note
Features and specifications are subject to change
without notice.
Flow Volume Measurements
Flow Volume

Type

Mass Flow sensor

Range

0-16 LPS

Resolution

0.003 LPS from 0.20 – 16 LPS

Flow accuracy

±3% of reading or 0.25 LPS, whichever is greater, across the range of 0.2 to
12 LPS

Volume
accuracy

±3% of reading or 0,050 L, whichever is greater

Resistance

<1.5 cmH20/LPS at 12 LPS
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APPENDIX E

EXCLUDED GROUP (EXCLUDED ON THE BASIS OF NOT MEETING
CRITERIA AS SET OUT IN TABLE 6.1)
No
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

Reason for Exclusion
Early Glottic closure
Slow start
Slow start
Early Glottic closure
Slow start
Slow start
end of test not met
only 2 acc tests
end of test not met
only 2 acc tests
end of test not met
end of test not met
end of test not met
Slow start
cough
end of test not met
end of test not met
cough
end of test not met
end of test not met
non-reproducible
cough
cough
Slow start
glottic closure
non-reproducible
glottic closure
end of test not met
cough
end of test not met
end of test not met
end of test not met
Slow start
cough
end of test not met
end of test not met
end of test not met
end of test not met
non-reproducible
non-reproducible
Slow start
Slow start
non-reproducible
non-reproducible
non-reproducible
end of test not met
non-reproducible
cough
Slow start
cough
non-reproducible

Hgt
161
154
159
157
163
187
176
173
176
153
173
156
144
161
166
170
170
159
165
185
184
164
174
172
165
158
174
178
153
188
149
177
162
158
167
184
177
150
166
156
175
189
174
177
169
169
161
159
164
174
167

FET
7.31
9.34
7.07
9.7
6.45
8.46
8.75
6.44
9.66
7.08
8.46
10.88
6.05
9.17
10.14
10.14
14.2
7.4
7.19
13.78
12.11
7.54
15.98
7.06
6.67
12.22
6.61
6.36
9.17
7.01
6.38
6.73
7.57
7.46
9.74
7.74
8.34
11.18
6.54
10.75
11.18
11.23
6.55
9.02
8.33
7.19
6.37
9.62
6.8
6.72
20.04

Gender
Female
Female
Male
Female
Female
Male
Male
Male
Male
Female
Male
Female
Female
Female
Male
Male
Male
Female
Female
Male
Male
Female
Male
Male
Female
Female
Male
Male
Female
Male
Female
Male
Female
Female
Male
Male
Male
Female
Female
Female
Male
Male
Male
Male
Male
Female
Female
Female
Female
Male
Male
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FEV1/FVC M
89
58
81
75
72
78
74
89
66
74
84
69
74
66
70
47
47
59
85
38
67
80
59
80
82
69
87
98
69
96
58
86
84
78
57
77
50
75
87
60
38
72
46
80
78
73
74
44
74
86
47

FEV1/FEV6M
89
63
81
77
73
80
76
91
69
74
86
75
76
69
73
53
55
59
85
48
72
80
69
81
82
75
88
98
72
96
58
86
84
80
61
80
55
80
87
66
44
75
46
83
79
73
74
50
75
86
60

52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72

end of test not met
Slow start
non-reproducible
non-reproducible
end of test not met
non-reproducible
non-reproducible
non-reproducible
non-reproducible
non-reproducible
Slow start
cough
non-reproducible
non-reproducible
cough
non-reproducible
end of test not met
end of test not met
end of test not met
end of test not met
non-reproducible

169
184
159
171
161
174
174
178
177
179
165
155
186
178
176
159
172
155
174
159
159

9.33
11.12
6.83
6.51
6.55
9.74
10.22
6.27
7.04
6.89
8.9
6.69
6.73
12.18
6.83
8.14
7.87
6.02
13.06
8.08
8.24

Female
Male
Female
Male
Female
Male
Male
Male
Male
Male
Female
Female
Male
Male
Male
Female
Male
Female
Male
Female
Female

73
62
71
75
76
55
65
85
85
81
73
71
75
55
65
73
60
70
54
82
53

76
68
72
75
77
59
69
86
85
82
75
72
75
61
66
77
63
71
62
84
55

Total (% of total)
Male
Female
72
39(54%)
33 (46%)
Non-smokers:
35
18
17
Ex-Smokers:
25
17
8
Smokers:
12
4
8
Age (Years)
60
58
62
FET (Seconds)
8.71
9.29
8.02
Height (Centimetres)
168
176
159
FVC
2.98
3.64
2.21
FEV6
2.86
3.45
2.15
FEV1
2.14
2.58
1.62
FEV1/FVC
70.3
69.1
71.8
FEV1/FEV6
73.0
72.3
73.8
Slow start
12 (16.6%)
6 (15.5%)
6 (18.2%)
EOT not met
24 (33.4%)
14 (35.9%)
10 (30.3%)
Not reproducible
22 (30.5%)
14 (35.9%)
8 (24.2%)
Cough
10 (13.9%)
4 (10.2%)
6 (18.2%)
Glottis closure
4 (5.6%)
1 (2.5%)
3 (9.1%)
FVC: forced vital capacity; FEV1: forced expiratory volume in one second; FEVt: forced expiratory
volume in t seconds; EOT: end of test;

149

APPENDIX F
NHANES III PREDICTION AND LOWER LIMIT OF NORMAL
EQUATIONS FOR FEV1/FEV6% AND FEV1/FVC% FOR CAUCAUSIAN
MALE AND FEMALE SUBJECTS AGED 8-80 YEARS

InterceptPRD

Age

InterceptLLN

R2

Male subjects
Caucasian
FEV1/FEV6%

87.340

0.1382

78.372

0.2151

FEV1/FVC%

88.066

0.2066

78.388

0.3448

FEV1/FEV6%

90.107

0.1563

81.307

0.3048

FEV1/FVC%

90.809

0.2125

81.015

0.3955

Female subjects
Caucasian

*

InterceptPRD is used for prediction equation and InterceptLLN is used (replaces
InterceptPRD) for the lower limit of normal equation. Lung function parameter = b0 + b1
* age.
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APPENDIX G
GARCIA-RIO PREDICTED EQUATIONS FOR HEALTHY CAUCASIAN
EUROPEAN MALES AGED 65-85YRS

Equation

R2

RSD

FVC L

0.0001572H2–0.00000268A3+0.223

0.477

0.4458

FEV1 L

0.0001107H2–0.0445A+2.886

0.464

0.3797

–0.00198A2+87.472

0.083

5.2655

FEV0.5 L

0.02615H–0.0372A+0.538

0.411

0.3305

FEV2 L

0.0001331H2–0.00000283A3+0.499

0.488

0.4066

FEV3 L

0.0001414H2–0.0000028A3+0.420

0.488

0.4174

FEV6 L

0.0001501H2–0.000298A2+0.869

0.483

0.4288

–0.0000172A3+85.536

0.086

5.0040

FEF25% L·s–1

0.04185H–0.137A+8.947

0.226

1.5178

FEF50% L·s–1

0.03174H–0.0754A+3.176

0.170

1.0573

FEF75% L·s–1

0.009789H–0.0184A+0.355

0.163

0.2776

0.07092H–0.000939A2+0.347

0.221

1.7378

FEF75–25% L·s–1

0.02635H–0.0604A+2.042

0.219

0.7241

FEF75–85% L·s–1

0.007765H–0.00948A–0.229

0.149

0.1779

TC25–50% s

0.00005571A2+0.153

0.045

0.2041

MTT s

0.00002282A2+0.223

0.054

0.0760

AEX L2·s–1

0.0007148H2–0.379A+18.788

0.397

3.3119

PIF L

0.0002211H2–0.0909A+4.621

0.247

1.2465

MIF50% L·s–1

0.0002133H2–0.0856A+4.128

0.221

1.2759

FIV1 L

0.0001585H2–0.0526A+2.592

0.373

0.5967

FEV1/FVC %

FEV1/FEV6 %

PEF L·s–1
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The lower limit of the normal is computed as: predicted value–1.645xresidual standard
deviation (RSD)
R2: adjusted coefficient of determination

GARCIA-RIO PREDICTED EQUATIONS FOR HEALTHY CAUCASIAN
EUROPEAN FEMALES AGED 65-85YRS
R2

Equation

FVC L
FEV1 L
FEV1/FVC %

0.0003171H2–0.0351A–6.368BSA+0.05925W+3.960

RSD

0.589 0.3046

0.0001726H2–0.0326A–2.303BSA+0.000122W2+3.398 0.527 0.2741
–0.155H–0.184A+116.096

0.048 5.4974

FEV0.5 L

0.00008072H2–0.0251A+1.436

0.432 0.2589

FEV2 L

0.0001138H2–0.0334A+1.844

0.523 0.2963

FEV3 L

0.0001218H2–0.0336A+1.774

0.529 0.3056

FEV6 L

0.0003309H2–0.0346A–6.987BSA+0.06548W+4.152

0.566 0.3101

–0.181H–0.178A+120.544

0.058 5.3530

FEF25% L·s–1

0.05351H–0.00000343A3–2.756

0.167 1.1193

FEF50% L·s–1

0.03414H–0.0540A+0.890

0.188 0.8234

FEF75% L·s–1

0.005960H–0.0150A+0.660

0.131 0.2467

0.0002283H2–0.0644A+4.001

0.209 1.1932

FEF75–25% L·s–1

0.02030H–0.0440A+1.538

0.202 0.5828

FEF75–85% L·s–1

–0.0644A+0.735

0.062 0.1345

TC25–50% s

0.0000003057A3+0.288

0.025 0.1743

AEX L2·s–1

0.0005499H2–0.158A+3.788

0.419 1.7560

PIF L

0.03154H–0.0553A+2.139

0.153 0.9248

MIF50% L·s–1

0.02934H–0.0566A+2.363

0.143 0.9552

FEV1/FEV6 %

PEF L·s–1

FIV1 L

3

0.03478H–0.143A+0.000006A +4.701

0.411 0.3866

The lower limit of the normal is computed as: predicted value–1.645xresidual standard
deviation (RSD)
R2: adjusted coefficient of determination
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APPENDIX H
1. Irish Thoracic Society (ITS), Galway 2005-Oral presentation
(Irish Journal of Medical Science Supplement 3, Volume 174 Number 4)
2. European Respiratory Society , Munich 2006-Thematic poster presentation
Abstract Number: 253038

Title: FEV1/FEV6 as an alternative to FEV1/FVC in diagnosing airway obstruction
using USA and European reference values in an elderly Irish population.
Janine M Kelly1, Patrick J Manning 1and Patrick G Goodman2. 1Respiratory,Bon
Secours Hospital, Glasnevin, Dublin 9,Ireland and 2School of Physics, Dublin Institute
of Technology, Kevin Street, Dublin 8,Ireland.
Introduction:
This study evaluates the use of FEV1/FEV6 as an alternative to FEV1/FVC in diagnosing
airway obstruction, especially for patients who cannot provide a satisfactory FVC end
of test criteria. This was done using US and European reference values with an elderly
Irish patient group, age 65-85yrs, the only age group for which European reference
values are available.
Method:
A retrospective analysis was conducted on spirometry data for 68 patients aged 6585yrs who exhaled for at least six seconds who met ATS criteria. Coefficient of
variance for both reference sets and the sensitivity and specificity of FEV1/FEV6 for
diagnosing airways obstruction as defined by FEV1/FVC was calculated.
Results:
Sensitivity %
Specificity %
Positive predictive value %
Negative predictive value%
Coefficient of variation %

Using USA reference values
100
97.9
94.7
100
FEV1/FVC = 17.8%
FEV1/FEV6=13.7%

Using European reference values
100
95.5
91.6
100
FEV1/FVC = 18.3%
FEV1/FEV6%=14.3%

Conclusions:
This study has shown reduced variability of FEV1/FEV6 compared to FEV1/FVC
demonstrating that FEV6 has a role in spirometry testing, especially for patients unable
to reach a satisfactory FVC endpoint. The agreement of FEV1/FVC and FEV1/FEV6
using both reference sets and the sensitivity/specificity of FEV1/FEV6 in this cohort
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support the validity of using FEV6 in the diagnosis of airway obstruction. This work
highlights the need for updated European reference values for FEV6 for all age groups.
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